2023

Cohen, O., Rendas-Baum, R., McCausland, K., Foard, D., Manwani, R., Ravichandran, S., ...Hawkins, P.N. (2023). Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis.. British Journal of Haematology, doi:10.1111/bjh.18645
Vergaro, G., Castiglione, V., Aimo, A., Prontera, C., Masotti, S., Musetti, V., ...Georgiopoulos, G. (2023). NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis.. European Journal of Heart Failure, doi:10.1002/ejhf.2769
Porcari, A., Razvi, Y., Masi, A., Patel, R., Ioannou, A., Rauf, M.U., ...Martinez-Naharro, A. (2023). Prevalence, Characteristics and Outcomes of Older Patients with Hereditary versus Wild-Type Transthyretin Amyloid Cardiomyopathy.. European Journal of Heart Failure, doi:10.1002/ejhf.2776
Ioannou, A., Fontana, M., Gillmore, J.D. (2023). RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis. BioDrugs, doi:10.1007/s40259-023-00577-7
Rauf, M.U., Hawkins, P.N., Cappelli, F., Perfetto, F., Zampieri, M., Argiro, A., ...Razvi, Y. (2023). Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis.. European heart journal, ehad139-. doi:10.1093/eurheartj/ehad139
Di Silvestre, D., Brambilla, F., Lavatelli, F., Chirivì, M., Canetti, D., Bearzi, C., ...Bellotti, V. (2023). The Protein Network in Subcutaneous Fat Biopsies from Patients with AL Amyloidosis: More Than Diagnosis?. Cells, 12 (5), doi:10.3390/cells12050699

2022

O'Donnell, L., Rossor, A., laura, M., Gillmore, J., Reilly, M. (2022). A CROSS-SECTIONAL ANALYSIS OF SPINAL MRI FINDINGS IN UK HATTR.
Razvi, Y., Ioannou, A., Chacko, L., Patel, R., Ganesananthan, S., Kaza, N., ...Venneri, L. (2022). A multi-modality, multi-parametric phenotyping study of transthyretin amyloid cardiomyopathy associated with the p.V1421 TTR variant.
Ravichandran, S., Mahmood, S., Wisniowski, B., Sachchithanantham, S., Popat, R., Lachmann, H., ...Kyriakou, C. (2022). A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.. British Journal of Haematology, doi:10.1111/bjh.18216
Faravelli, G., Mondani, V., Mangione, P.P., Raimondi, S., Marchese, L., Lavatelli, F., ...Verona, G. (2022). Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 9 doi:10.3389/fmolb.2022.830006
Pimenta, D., Taubel, J., Anyim, M., Gillmore, J.D., Zhu, T., Rezk, T. (2022). Assessing Disease Severity Using Machine-Learning of Baseline 12-Lead Ecg Parameters in Attr Cardiac Amyloidosis.
Razvi, Y., Porcari, A., Di Nora, C., Patel, R.K., Ioannou, A., Rauf, M.U., ...Rezk, T. (2022). Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience. Frontiers in Cardiovascular Medicine, 9 doi:10.3389/fcvm.2022.1075806
Razvi, Y., Patel, R., Ioannou, A., Rauf, M.U., Masi, A., Porcari, A., ...Whelan, C. (2022). Cardiac transplantation in transthyretin amyloid cardiomyopathy: outcomes from three decades of tertiary centre experience.
Martinez-Naharro, A., Patel, R., Kotecha, T., Karia, N., Ioannou, A., Petrie, A., ...Brown, J. (2022). Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment. EUROPEAN HEART JOURNAL, doi:10.1093/eurheartj/ehac363
Ioannou, A., Patel, R., Porcari, A., Venneri, L., Masi, A., Massa, P., ...Chacko, L. (2022). Changes in Clinical Phenotype of Patients With ATTR Cardiac Amyloidosis During the Past 20 Years.
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Venneri, L., Bandera, F., ...Ganesananthan, S. (2022). Changes in referral pathway and phenotypic status of patients diagnosed with ATTR cardiac amyloidosis during the past 20 years.
Law, S., Bezard, M., Petrie, A., Chacko, L., Cohen, O.C., Ravichandran, S., ...Ganeshananthan, S. (2022). Characteristics and natural history of early-stage cardiac transthyretin amyloidosis.. Eur Heart J, doi:10.1093/eurheartj/ehac259
Coelho, T., Waddington Cruz, M., Chao, C.-.C., Parman, Y., Wixner, J., Weiler, M., ...Schneider, E. (2022). Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Neurology and Therapy, doi:10.1007/s40120-022-00414-z
Gillmore, J.D., Reilly, M.M., Coats, C.J., Cooper, R., Cox, H., Coyne, M.R.E., ...Hawkins, P.N. (2022). Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK. Advances in Therapy, doi:10.1007/s12325-022-02139-9
Porcari, A., Fontana, M., Canepa, M., Biagini, E., Cappelli, F., Gagliardi, C., ...Dore, F. (2022). CLINICAL AND PROGNOSTIC IMPLICATIONS OF RV UPTAKE WITH RADIONUCLIDE SCINTIGRAPHY IN TRANSTHYRETIN CARDIAC AMYLOIDOSIS.
Bandera, F., Martone, R., Chacko, L., Ganesananthan, S., Gilbertson, J.A., Ponticos, M., ...Quarta, C. (2022). Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 15 (1), 17-29. doi:10.1016/j.jcmg.2021.06.022
Somers, H., Tanzim, U., Porcari, A., Razvi, Y., Rezk, T., Patel, R., ...Hutt, D.F. (2022). Comparison of ^99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 15 (7), 1353-1355. doi:10.1016/j.jcmg.2022.02.016
Porcari, A., Hutt, D.F., Grigore, S.F., Quigley, A.-.M., Rowczenio, D., Gilbertson, J., ...Rauf, M.U. (2022). Comparison of Different Technetium-99m-Labeled Bone Tracers for Imaging Cardiac Amyloidosis.. European Journal of Preventive Cardiology, doi:10.1093/eurjpc/zwac237
Rapezzi, C., Aimo, A., Serenelli, M., Barison, A., Vergaro, G., Passino, C., ...Fontana, M. (2022). Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79 (13), 1288-1303. doi:10.1016/j.jacc.2022.01.036
Ravichandran, S., Law, S., Mahmood, S., Wisniowski, B., Foard, D., Fontana, M., ...Lachmann, H.J. (2022). Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis. Leukemia, doi:10.1038/s41375-021-01497-7
Adams, D., Tournev, I.L., Taylor, M.S., Coelho, T., Planté-Bordeneuve, V., Berk, J.L., ...Sekijima, Y. (2022). Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid, doi:10.1080/13506129.2022.2091985
Gama, F., Rosmini, S., Bandula, S., Patel, K.P., Massa, P., Tobon-Gomez, C., ...Thornton, G.D. (2022). Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis.. JACC Cardiovasc Imaging, doi:10.1016/j.jcmg.2022.08.006
Gillmore, J.D., Taubel, J., Gane, E., Pilebro, B., Maitland, M.L., Stroh, M., ...Gutstein, D.E. (2022). First-in-Human in vivo CRISPR/Cas9 Editing of the TTR Gene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy.
Law, S., Arnold, J., Rauf, M.U., Heptinstall, L., Gilbertson, J., Rowczenio, D., ...Gillmore, J.D. (2022). Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report. American Journal of Kidney Diseases, doi:10.1053/j.ajkd.2022.08.018
Mussinelli, R., Garcia-pavia, P., Gillmore, J.D., Kale, P., Berk, J.L., Maurer, M.S., ...Chen, C. (2022). HELIOS-A: 18-MONTH EXPLORATORY CARDIAC RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS.
Remiche, G., Adams, D., Taylor, M.S., Plante-Bordeneuve, V., Berk, J.L., Gonzales-Duarte, A., ...Obici, L. (2022). HELIOS-A: 9-month subgroup analyses and exploratory efficacy results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Ajroud-Driss, S., Berk, J., Adams, D., Gillmore, J.D., Lin, K.-.P., Kale, P., ...Vest, J. (2022). HELIOS-A: IMPACT OF VUTRISIRAN ON QUALITY OF LIFE AND FUNCTIONAL STATUS IN HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY.
Gonzalez-Duarte, A., Adams, D., Tournev, I., Taylor, M., Coelho, T., Plante-Bordeneuve, V., ...Sekijima, Y. (2022). HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY.
Adams, D., Tournev, I.L., Taylor, M.S., Coelho, T., Plante-Bordeneuve, V., Berk, J.L., ...Sekijima, Y. (2022). HELIOS-A: STUDY OF VUTRISIRAN IN PATIENTS WITH HATTR AMYLOIDOSIS.
Barnett, J.E.F., Gilbertson, J.A., Arrow, N., Gillmore, J.D., Hawkins, P.N., Larbalestier, L., ...Wessels, M.E. (2022). Hepatic Amyloidosis in a Chronically Entangled Grey Seal (Halichoerus grypus).. Journal of Comparative Pathology, 199 1-7. doi:10.1016/j.jcpa.2022.09.003
Ladefoged, B., Clemmensen, T., Dybro, A., Hartig-Andreasen, C., Kirkeby, L., Gormsen, L.C., ...Poulsen, S.H. (2022). Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS). ESC Heart Failure, doi:10.1002/ehf2.14173
Ioannou, A., Patel, R., Gillmore, J.D., Fontana, M. (2022). Imaging-Guided Treatment for Cardiac Amyloidosis. Current Cardiology Reports, doi:10.1007/s11886-022-01703-7
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Sinagra, G., Venneri, L., ...O'Beara, S. (2022). Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation, doi:10.1161/CIRCULATIONAHA.122.060852
Ladefoged, B.T., Dybro, A., Dahl Pedersen, A.L., Rasmussen, T.B., Vase, H.O., Clemmensen, T.S., ...Poulsen, S.H. (2022). Incidence and predictors of worsening heart failure in patients with wild-type transthyretin cardiac amyloidosis. ESC HEART FAILURE, 9 (5), 2978-2987. doi:10.1002/ehf2.14000
Porcari, A., Fontana, M., Gillmore, J.D. (2022). Letter by Porcari et al Regarding Article, "Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation".. Circ Cardiovasc Imaging, 101161CIRCIMAGING12201469. doi:10.1161/CIRCIMAGING.122.014692
Brannagan, T.H., Berk, J.L., Gillmore, J.D., Maurer, M.S., Waddington-Cruz, M., Fontana, M., ...Baker, B.F. (2022). Liver Directed Drugs for Transthyretin-Mediated Amyloidosis.. Journal of the Peripheral Nervous System, doi:10.1111/jns.12519
Cohen, O.C., Ismael, A., Pawarova, B., Manwani, R., Ravichandran, S., Law, S., ...Douglas, B. (2022). Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. European Heart Journal, doi:10.1093/eurheartj/ehab507
Ravichandran, S., Law, S., Mahmood, S., Wisniowski, B., Foard, D., Fontana, M., ...Gillmore, J.D. (2022). Long-term outcomes in light chain deposition disease- analysis of a UK cohort.. American Journal of Hematology, doi:10.1002/ajh.26725
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Knight, D., Martinez-Naharro, A., ...Hawkins, P.N. (2022). Multi-imaging characterisation of cardiac phenotype in different types of amyloidosis.
Ioannou, A., Patel, R.K., Razvi, Y., Porcari, A., Knight, D., Martinez-Naharro, A., ...Brown, J. (2022). Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis. JACC: Cardiovascular Imaging, doi:10.1016/j.jcmg.2022.07.008
Ioannou, A., Chacko, L., Kotecha, T., Patel, R.K., Razvi, Y., Porcari, A., ...Brown, J. (2022). Myocardial ischaemia in cardiac amyloidosis: a change of perspective.
Castiglione, V., Aimo, A., Prontera, C., Masotti, S., Musetti, V., Nicol, M., ...Chubuchny, V. (2022). NT-PROBNP AND HIGH-SENSITIVITY TROPONIN T HOLD DIAGNOSTIC VALUE IN CARDIAC AMYLOIDOSIS.
Gillmore, J.D. (2022). Patisiran in clinical practice - Experience from the UK National Amyloidosis Centre.
Schmidt, H.H., Wixner, J., Planté-Bordeneuve, V., Muñoz-Beamud, F., Lladó, L., Gillmore, J.D., ...Jay, P.Y. (2022). Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.. American Journal of Transplantation, doi:10.1111/ajt.17009
Porcari, A., Razvi, Y., Masi, A., Patel, R., Ioannou, A., Rauf, M.U., ...Martinez-naharro, A. (2022). PREVALENCE, DISEASE CHARACTERISTICS AND OUTCOMES OF HEREDITARY TRANSTHYRETIN AMYLOID CARDIOMYOPATHY AMONG ELDERLY INDIVIDUALS.
Longhi, S., Maurer, M.S., Fontana, M., Berk, J.L., Gustafsson, F., Simoes, M., ...Kubanek, M. (2022). PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY.
Porcari, A., Pagura, L., Canepa, M., Biagini, E., Cappelli, F., Tini, G., ...Fontana, M. (2022). Prognostic implications of biventricular uptake of bone tracers at planar scintigraphy in transthyretin cardiac amyloidosis.
Porcari, A., Masi, A., Ioannou, A., Patel, R.K., Razvi, Y., Venneri, L., ...Hawkins, P.N. (2022). Prognostic implications of clinical phenotype and severity of cardiac involvement in patients presenting with immunoglobulin light chain amyloidosis.
Cohen, O.C., Sathyanath, A., Petrie, A., Ravichandran, S., Law, S., Manwani, R., ...Martinez-Naharro, A. (2022). Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.. Heart, doi:10.1136/heartjnl-2021-320703
Chacko, L., Karia, N., Venneri, L., Bandera, F., Dal Passo, B., Buonamici, L., ...Patel, R. (2022). Progression of echocardiographic parameters and prognosis in ATTR cardiac amyloidosis.. European Journal of Heart Failure, doi:10.1002/ejhf.2606
Patel, R., Martinez-Naharro, A., Kotecha, T., Karia, N., Ioannou, A., Petrie, A., ...Venneri, L. (2022). Progression, regression and redefining the treatment response - cardiac magnetic resonance with T1 and extracellular volume mapping in cardiac light-chain amyloidosis.
Aimo, A., Castiglione, V., Rapezzi, C., Franzini, M., Panichella, G., Vergaro, G., ...Emdin, M. (2022). RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, doi:10.1038/s41569-022-00683-z
Patel, R.K., Ioannou, A., Razvi, Y., Chacko, L., Venneri, L., Bandera, F., ...Masi, A. (2022). Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis. European Journal of Heart Failure, doi:10.1002/ejhf.2646
Patel, R., Ioannou, A., Razvi, Y., Chacko, L., Venneri, L., Martinez-Naharro, A., ...Petrie, A. (2022). Size matters - redefining sex differences among patients with transthyretin amyloid cardiomyopathy - have we been wrong all along?.
Vilches, S., Fontana, M., Gonzalez-Lopez, E., Mitrani, L., Saturi, G., Renju, M., ...De Los Santos, J. (2022). Systemic Embolism in Amyloid Transthyretin Cardiomyopathy. European Journal of Heart Failure, doi:10.1002/ejhf.2566
Cohen, O.C., Blakeney, I.J., Law, S., Ravichandran, S., Gilbertson, J., Rowczenio, D., ...Lachmann, H.J. (2022). The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre. Amyloid, doi:10.1080/13506129.2022.2070741
Porcari, A., Fontana, M., Gillmore, J.D. (2022). Transthyretin cardiac amyloidosis. Cardiovascular Research, doi:10.1093/cvr/cvac119
Tsamis, K.I., Mytilinaios, D., Heneghan, M., Gillmore, J.D., Gilbertson, J.A., Giannopoulos, S., ...Konitsiotis, S. (2022). Treatment of Acquired Transthyretin Amyloidosis in Domino Liver Transplantation.. Clinical Transplantation, e14822. doi:10.1111/ctr.14822
Bomsztyk, J., Ravichandran, S., Giles, H.V., Berlanga, O., Harding, S., Khwaja, J., ...Foard, D. (2022). Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis.
Law, S., Gillmore, J.D. (2022). When to suspect and how to approach a diagnosis of amyloidosis.. American Journal of Medicine, doi:10.1016/j.amjmed.2022.01.004

2021

Quarta, C.C., Zheng, J., Hutt, D., Grigore, S.F., Manwani, R., Sachchithanantham, S., ...Martinez-Naharro, A. (2021). {99m}^Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging, doi:10.1093/ehjci/jeab095
Rezk, T., Fontana, M., Gillmore, J.D. (2021). A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis. Expert Opinion on Orphan Drugs, doi:10.1080/21678707.2021.1898371
Damy, T., Conceição, I., García-Pavía, P., Gillmore, J., Jandhyala, R., Sabbat, J., ...Coelho, T. (2021). A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid, 1-10. doi:10.1080/13506129.2021.1931099
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2 - evidence base and standardized methods of imaging.. Journal of Cardiac Failure, doi:10.1016/j.cardfail.2021.06.012
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. JOURNAL OF NUCLEAR CARDIOLOGY, 28 (4), 1769-1774. doi:10.1007/s12350-020-02455-z
Law, S., Fontana, M., Gillmore, J.D. (2021). Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. Cardiology Clinics, 39 (3), 389-402. doi:10.1016/j.ccl.2021.04.010
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, HCI0000000000000029. doi:10.1161/HCI.0000000000000029
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging (vol 26, pg 2065, 2019). JOURNAL OF NUCLEAR CARDIOLOGY, 28 (4), 1761-1762. doi:10.1007/s12350-021-02711-w
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, HCI0000000000000030. doi:10.1161/HCI.0000000000000030
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2021). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization (vol 27, pg 659, 2020). JOURNAL OF NUCLEAR CARDIOLOGY, 28 (4), 1763-1767. doi:10.1007/s12350-021-02712-9
Fontana, M., Martinez-Naharro, A., Chacko, L., Rowczenio, D., Gilbertson, J.A., Whelan, C.J., ...Hutt, D.F. (2021). Assessing Cardiac Response to Patisiran by Changes in Extracellular Volume Potential Issues REPLY. JACC-CARDIOVASCULAR IMAGING, 14 (4), 882-883. doi:10.1016/j.jcmg.2021.02.003
Parker, M.M., Damrauer, S.M., Tcheandjieu, C., Erbe, D., Aldinc, E., Hawkins, P.N., ...Joseph, J. (2021). Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry. Scientific Reports, 11 (1), doi:10.1038/s41598-021-91113-6
Bandera, F., Martone, R., Chacko, L., Ponticos, M., Lane, T., Martinez-Naharro, A., ...Patel, R. (2021). Atrial Myopathy in Amyloidosis REPLY. JACC-CARDIOVASCULAR IMAGING, 14 (11), 2268-2269. doi:10.1016/j.jcmg.2021.09.025
Brannagan, T.H., Auer-Grumbach, M., Berk, J.L., Briani, C., Bril, V., Coelho, T., ...Fine, N. (2021). ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.. Orphanet Journal of Rare Diseases, 16 (1), 204. doi:10.1186/s13023-021-01834-0
Sharpley, F.A., Manwani, R., Petrie, A., Mahmood, S., Sachchithanantham, S., Lachmann, H.J., ...Fontana, M. (2021). Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK. European Journal of Haematology, doi:10.1111/ejh.13582
Razvi, Y., Patel, R.K., Fontana, M., Gillmore, J.D. (2021). Cardiac Amyloidosis: A Review of Current Imaging Techniques. Frontiers in Cardiovascular Medicine, 8 doi:10.3389/fcvm.2021.751293
Chacko, L., Boldrini, M., Martone, R., Law, S., Martinez-Naharrro, A., Hutt, D.F., ...Rezk, T. (2021). Cardiac Magnetic Resonance-Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid.. Circ Cardiovasc Imaging, CIRCIMAGING121012506. doi:10.1161/CIRCIMAGING.121.012506
Law, S., Petrie, A., Chacko, L., Cohen, O.C., Ravichandran, S., Gilbertson, J.A., ...Lachmann, H.J. (2021). Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, doi:10.1136/heartjnl-2021-319063
Canetti, D., Brambilla, F., Rendell, N.B., Nocerino, P., Gilbertson, J.A., Di Silvestre, D., ...Gillmore, J.D. (2021). Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing Between Two Centres.. Molecules, 26 (7), doi:10.3390/molecules26071913
Canetti, D., Nocerino, P., Rendell, N.B., Botcher, N., Gilbertson, J.A., Blanco, A., ...Corazza, A. (2021). Clinical ApoA-IV amyloid is associated with fibrillogenic signal sequence.. Journal of Pathology, doi:10.1002/path.5770
Gillmore, J.D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M.L., ...Wood, K. (2021). CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. New England Journal of Medicine, doi:10.1056/NEJMoa2107454
Gillmore, J.D., Maitland, M.L., Lebwohl, D. (2021). CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis: response [The authors reply]. New England Journal of Medicine, 385 (18), 1722-1723. doi:10.1056/NEJMc2114592
Coelho, T., Ando, Y., Benson, M.D., Berk, J.L., Waddington-Cruz, M., Dyck, P.J., ...Obici, L. (2021). Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy.. Neurol Ther, doi:10.1007/s40120-021-00235-6
Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., ...Eriksson, U. (2021). Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.. Eur J Heart Fail, doi:10.1002/ejhf.2140
Garcia-Pavia, P., Rapezzi, C., Adler, Y., Arad, M., Basso, C., Brucato, A., ...Eriksson, U. (2021). Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.. Eur Heart J, doi:10.1093/eurheartj/ehab072
Ravichandran, S., Law, S., Mahmood, S., Wisniowski, B., Foard, D., Fontana, M., ...Lachmann, H. (2021). Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
Cechin, L., Gasmelseed, J., Bashford, J., Rowczenio, D., Reilly, M.M., Gillmore, J.D., Coutinho, E. (2021). Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis.. Neurology: Clinical Practice, 11 (5), e757-e759. doi:10.1212/CPJ.0000000000001054
Muchtar, E., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schoenland, S., ...Kumar, S. (2021). Graded Renal Response Criteria for Light Chain (AL) Amyloidosis.
Ravichandran, S., Cohen, O.C., Law, S., Sachchithanantham, S., Mahmood, S., Foard, D., ...Gillmore, J.D. (2021). Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data. British Journal of Haematology, doi:10.1111/bjh.17636
Adams, D., Tournev, I., Taylor, M., Coelho, T., Plante-Bordeneuve, V., Berk, J., ...Sekijima, Y. (2021). HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Adams, D., Tournev, I., Taylor, M., Coelho, T., Plante-Bordeneuve, V., Berk, J., ...Sekijima, Y. (2021). HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Adams, D., Tournev, I.L., Taylor, M.S., Coelho, T., Plante-Bordeneuve, V., Berk, J.L., ...Sekijima, Y. (2021). HELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Adams, D., Tournev, I., Taylor, M., Coelho, T., Plante-Bordeneuve, V., Berk, J., ...Sekijima, Y. (2021). HELIOS-A: NINE-MONTH RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY.
Patel, K.P., Scully, P.R., Nitsche, C., Kammerlander, A.A., Joy, G., Thornton, G., ...Captur, G. (2021). Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis. Heart, doi:10.1136/heartjnl-2021-319922
Ravichandran, S., Cohen, O.C., Law, S., Foard, D., Fontana, M., Martinez-Naharro, A., ...Sachchithanantham, S. (2021). Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer Journal, 11 (6), doi:10.1038/s41408-021-00510-7
Gillmore, J., Taubel, J., Kao, J., Fontana, M., Maitland, M., Seitzer, J., ...Xu, Y. (2021). In vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 in patients with transthyretin amyloidosis (late breaking abstract).
Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A.V., Schmidt, H.H., ...Quan, D. (2021). Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. The Lancet Neurology, doi:10.1016/S1474-4422(20)30368-9
Coelho, T., Ando, Y., Benson, M., Berk, J., Cruz, M.W., Dyck, P., ...Obici, L. (2021). NEURO-TTRansform: Phase 3 study to evaluate AKCEA-TTR-LRx in patients with hATTR-PN.
Mazzeo, A., Munoz-Beamud, F., Coelho, T., Gillmore, J., Adams, D., Wixner, J., ...White, M.T. (2021). Patisiran in patients with hATTR amyloidosis post-orthopedic liver transplant: 12-month results.
Munoz-Beamud, F., Coelho, T., Gillmore, J.D., Adams, D., Mazzeo, A., Wixner, J., ...White, M.T. (2021). Patisiran in patients with hATTR amyloidosis post-orthotopic liver transplant: 12-month results.
Slamova, I., Adib, R., Ellmerich, S., Golos, M.R., Gilbertson, J.A., Botcher, N., ...Tennent, G.A. (2021). Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 12 (1), doi:10.1038/s41467-021-27416-z
Law, S., Cohen, O., Lachmann, H., Rezk, T., Gilbertson, J., Rowczenio, D., ...Gillmore, J. (2021). Renal Transplant Outcomes in Amyloidosis. Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa293
Patel, R.K., Fontana, M., Hawkins, P.N., Gillmore, J. (2021). Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.. Amyloid, 1-2. doi:10.1080/13506129.2021.1920389
Ross, J.C., Hutt, D.F., Burniston, M., Grigore, S.F., Fontana, M., Page, J., ...Gillmore, J.D. (2021). The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid, 1-12. doi:10.1080/13506129.2021.1991302
Benson, M.D., Berk, J.L., Dispenzieri, A., Damy, T., Gillmore, J.D., Hazenberg, B.P., ...Schönland, S. (2021). Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid, doi:10.1080/13506129.2021.1994386
Mooney, S., Ndukwe, I., Murphy, S., Joyce, E., Gillmore, J., Tubridy, N., ...Kinsella, J. (2021). Unusual, Stable Phenotype in Patient with Ser70Arg TTR Mutation on Diflunisal Therapy.
Rezk, T., Salota, R., Gan, J.J., Lachmann, H.J., Fontana, M., Siew, K., ...Sachchithanantham, S. (2021). Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light-chain (AL) amyloidosis. British Journal of Haematology, doi:10.1111/bjh.17706

2020

Sharpley, F.A., Fontana, M., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N., Mahmood, S., ...Rezk, T.M. (2020). Amyloidosis Diagnosed in Solid Organ Transplant Recipients.. Transplantation, 104 (2), 415-420. doi:10.1097/TP.0000000000002813
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2020). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, doi:10.1007/s12350-019-01761-5
Bandera, F., Martone, R., Chacko, L., Ganesananthan, S., Lane, T., Martinez-Naharro, A., ...Gilbertson, J.A. (2020). Atrial strain in cardiacATTR amyloidosis from pathophysiology to prognosis: is it time to rethink our approach to disease?.
Gertz, M., Adams, D., Ando, Y., Beirão, J.M., Bokhari, S., Coelho, T., ...Drachman, B.M. (2020). Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.. BMC Fam Pract, 21 (1), 198. doi:10.1186/s12875-020-01252-4
Bandera, F., Martone, R., Chacko, L., Ganesananthan, S., Lane, T., Martinez-Naharro, A., ...Ponticos, M. (2020). Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis.
Raimondi, S., Mangione, P.P., Verona, G., Canetti, D., Nocerino, P., Marchese, L., ...Taylor, G.W. (2020). Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, doi:10.1074/jbc.RA120.014026
Gibier, J.-.B., Gilbertson, J.A., Perbet, R., Leriche, W., Truant, S., Leteurtre, E., ...Gnemmi, V. (2020). Découverte fortuite d’une atteinte hépatique d’amylose à leukocyte chemotactic factor 2 [Incidental finding of leukocyte cell-derived chemotaxin 2 - Associated amyloidosis in a liver].. Annales de Pathologie, doi:10.1016/j.annpat.2020.04.007
Canetti, D., Rendell, N.B., Gilbertson, J.A., Botcher, N., Nocerino, P., Blanco, A., ...Mangione, P.P. (2020). Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. Clinical Chemistry and Laboratory Medicine, doi:10.1515/cclm-2019-1007
Law, S., Petrie, A., Chacko, L., Cohen, O.C., Ravichandran, S., Gilbertson, J.A., ...Lachmann, H.J. (2020). Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, doi:10.1002/ehf2.12989
Chacko, L., Martone, R., Bandera, F., Lane, T., Martinez-Naharro, A., Boldrini, M., ...Rowczenio, D. (2020). Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, doi:10.1093/eurheartj/ehz905
Adams, D., Ando, Y., Beirão, J.M., Coelho, T., Gertz, M.A., Gillmore, J.D., ...Merlini, G. (2020). Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.. J Neurol, doi:10.1007/s00415-019-09688-0
Cohen, O., Ismail, A., Manwani, R., Ravichandran, S., Foard, D., Mahmood, S., ...Lachmann, H. (2020). Global longitudinal strain predicts survival and response in patients with systemic AL amyloidosis. analysis of 915 patients from the ALchemy prospective trial.
McGowan, C.R., Wright, T., Nitsch, D., Lewer, D., Brathwaite, R., Scott, J., ...Gillmore, J. (2020). High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. Scientific Reports, 10 (1), 7059. doi:10.1038/s41598-020-63748-4
Law, S., Gillmore, J., Gilbertson, J.A., Bass, P., Salama, A.D. (2020). Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis. BMC Nephrology, 21 (1), doi:10.1186/s12882-020-01733-9
Gillmore, J., Berk, J., Dispenzieri, A., Polydefkis, M., Gonzalez-Duarte, A., Sekijima, Y., ...White, M.T. (2020). Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Gillmore, J., Berk, J., Dispenzieri, A., Polydefkis, M., Gonzalez-Duarte, A., Sekijima, Y., ...White, M.T. (2020). Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Dispenzieri, A., Gillmore, J., Polydefkis, M., Plante-Bordeneuve, V., Schmidt, H., Berber, E., ...Maurer, M. (2020). LONG-TERM, INTEGRATED CARDIAC SAFETY OF PATISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY.
Moura, A., Nocerino, P., Gilbertson, J.A., Rendell, N.B., Mangione, P.P., Verona, G., ...Bellotti, V. (2020). Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein.. Amyloid, 1-2. doi:10.1080/13506129.2020.1720637
Baggiano, A., Boldrini, M., Martinez-Naharro, A., Kotecha, T., Petrie, A., Rezk, T., ...Wechalekar, A.D. (2020). Magnetic Resonance to Diagnose Cardiac Amyloidosis Is it Already Time to Discard Contrast Agents? REPLY. JACC-CARDIOVASCULAR IMAGING, 13 (5), 1294-1295. doi:10.1016/j.jcmg.2020.02.024
Boldrini, M., Cappelli, F., Chacko, L., Restrepo-Cordoba, M.A., Lopez-Sainz, A., Giannoni, A., ...Whelan, C. (2020). Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, doi:10.1016/j.jcmg.2019.10.011
Chacko, L., Kotecha, T., Martinez-Naharro, A., Brown, J., Rezk, T., Knott, K., ...Gonzalez, A. (2020). Myocardial Ischaemia in Cardiac Amyloidosis, Changing Perspectives.
Baggiano, A., Boldrini, M., Martinez-Naharro, A., Kotecha, T., Petrie, A., Rezk, T., ...Wechalekar, A.D. (2020). Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, doi:10.1016/j.jcmg.2019.03.026
Coelho, T., Gillmore, J., Adams, D., Munoz-Beamud, F., Mazzeo, A., Wixner, J., ...Wang, J.J. (2020). Open-label study of Patisiran in patients with hATTR amyloidosis post-orthotopic liver transplant.
Judge, D.P., Kristen, A.V., Grogan, M., Maurer, M.S., Falk, R.H., Hanna, M., ...Harrop, J. (2020). Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (vol 15, pg 613, 2020). CARDIOVASCULAR DRUGS AND THERAPY, 34 (6), 889. doi:10.1007/s10557-020-07023-8
Judge, D.P., Kristen, A.V., Grogan, M., Maurer, M.S., Falk, R.H., Hanna, M., ...Harrop, J. (2020). Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).. Cardiovasc Drugs Ther, doi:10.1007/s10557-019-06919-4
Obici, L., Berk, J.L., González-Duarte, A., Coelho, T., Gillmore, J., Schmidt, H.H.-.J., ...Brannagan, T.H. (2020). Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.. Amyloid, 1-10. doi:10.1080/13506129.2020.1730790
Cohen, O.C., Brodermann, M.H., Blakeney, I.J., Mahmood, S., Sachchithanantham, S., Ravichandran, S., ...Popat, R. (2020). Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. Amyloid, 1-6. doi:10.1080/13506129.2020.1765768
Fontana, M., Martinez-Naharro, A., Chacko, L., Rowczenio, D., Gilbertson, J.A., Whelan, C.J., ...Hutt, D.F. (2020). Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression.. JACC Cardiovasc Imaging, doi:10.1016/j.jcmg.2020.07.043
Chacko, L., Martinez-Naharro, A., Kotecha, T., Martone, R., Hutt, D., Lane, T., ...Hawkins, P. (2020). Regression of cardiac amyloid deposits with novel therapeutics: reaching new frontiers in cardiac ATTR amyloidosis.
Castiglione, V., Aimo, A., Giannoni, A., Chubuchny, V., Taddei, C., Ganesananthan, S., ...Gillmore, J. (2020). Sex-related differences in cardiac wild-type transthyretin amyloidosis.
Castiglione, V., Aimo, A., Giannoni, A., Chubuchny, V., Taddei, C., Ganesananthan, S., ...Gillmore, J. (2020). Sex-related differences in cardiac wild-type transthyretin amyloidosis.
Cohen, O.C., Law, S., Lachmann, H.J., Sharpley, F., Ravichandran, S., Mahmood, S., ...Fontana, M. (2020). The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.. Blood Cancer J, 10 (5), 60. doi:10.1038/s41408-020-0325-2
Cohen, O.C., Ismael, A., Manwani, R., Ravichandran, S., Law, S., Foard, D., ...Hawkins, P.N. (2020). The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis.
Cohen, O.C., Sathyanath, A., Ravichandran, S., Law, S., Manwani, R., Foard, D., ...Fontana, M. (2020). The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis.
Cohen, O., Brodermann, M.H., Blakeney, I.J., Mahmood, S., Sachchithanantham, S., Ravichandran, S., ...Cheesman, S. (2020). The UK experience of daratumumab monotherapy in relapsed systemic AL amyloidosis.
Parker, M.M., Damrauer, S.M., Tcheandjieu, C., Erbe, D., Aldinc, E., Hawkins, P.N., ...Joseph, J. (2020). The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy.
Cohen, O.C., Sharpley, F., Gilbertson, J.A., Wechalekar, A.D., Sachchithanantham, S., Mahmood, S., ...Lachmann, H.J. (2020). The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, doi:10.1111/ejh.13458
Papa, R., Gilbertson, J.A., Rendell, N., Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N., Lachmann, H.J. (2020). Two types of systemic amyloidosis in a single patient. Amyloid, 1-2. doi:10.1080/13506129.2020.1760238
Cohen, O.C., Sharpley, F., Gillmore, J.D., Lachmann, H.J., Sachchithanantham, S., Mahmood, S., ...Kyriakou, C. (2020). Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis. British Journal of Haematology, doi:10.1111/bjh.16401

2019

Sharpley, F.A., Petrie, A., Mahmood, S., Sachchithanantham, S., Lachmann, H.J., Gillmore, J.D., ...Quarta, C. (2019). A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.. British Journal of Haematology, doi:10.1111/bjh.16143
Sharpley, F.A., Manwani, R., Mahmood, S., Sachchithanantham, S., Lachmann, H.J., Gillmore, J.D., ...Wechalekar, A.D. (2019). A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.. Blood Cancer J, 9 (2), 16. doi:10.1038/s41408-019-0180-1
Garg, M., Hall, A., Jenner, M., Kishore, B., Lachmann, H.J., Gillmore, J.D., ...Mahmood, S. (2019). A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results.
Manwani, R., Page, J., Lane, T., Burniston, M., Skillen, A., Lachmann, H.J., ...Hawkins, P.N. (2019). A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.. Amyloid, 1-6. doi:10.1080/13506129.2018.1552852
Manwani, R., Cohen, O., Sharpley, F., Mahmood, S., Sachchithanantham, S., Foard, D., ...Gillmore, J.D. (2019). A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.. Blood, doi:10.1182/blood.2019000834
Lachmann, H.J., Rowczenio, D., Gilbertson, J.A., Noor, I., Trojer, H., Gillmore, J.D., ...Hawkins, P.N. (2019). AA AMYLOIDOSIS IN RECIPIENTS OF CADAVERIC DERIVED PITUITARY GROWTH HORMONE - POTENTIAL EFFECT OF AN AMYLOID ENHANCING FACTOR?.
Kotecha, T., Martinez-Naharro, A., Yoowannakul, S., Lambe, T., Rezk, T., Knight, D., ...Kellman, P. (2019). Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance. Scientific Reports, doi:10.1038/s41598-018-37845-4
Rowczenio, D., Quarta, C.C., Fontana, M., Whelan, C.J., Martinez-Naharro, A., Trojer, H., ...Rezk, T. (2019). Analysis of the TTR gene in the investigation of amyloidosis: A 25‐year single UK center experience. Human Mutation, doi:10.1002/humu.23669
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2019). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2—Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, doi:10.1016/j.cardfail.2019.08.001
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2019). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, doi:10.1007/s12350-019-01760-6
Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R.H., Ferrari, V.A., ...Glaudemans, A.W.J.M. (2019). ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2—Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, doi:10.1016/j.cardfail.2019.08.002
Gillmore, J.D., Garcia-Pavia, P., Grogan, M., Hanna, M.A., Heitner, S.B., Jacoby, D., ...Ganju, J. (2019). ATTRibute-CM: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Phase 3 Study of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
Rezk, T., Davenport, A., Gan, J.J., Lachmann, H.J., Fontana, M., Martinez-Naharro, A., ...Petrie, A. (2019). Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.. British Journal of Haematology, doi:10.1111/bjh.15675
Sharpley, F.A., Fontana, M., Martinez-Naharro, A., Manwani, R., Mahmood, S., Sachchithanantham, S., ...Hawkins, P.N. (2019). Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.. Haematologica, doi:10.3324/haematol.2019.217695
Rezk, T., Lachmann, H.J., Fontana, M., Naharro, A.M., Sachchithanantham, S., Mahmood, S., ...Foard, D. (2019). Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.. Br J Haematol, doi:10.1111/bjh.15955
Manwani, R., Mahmood, S., Sachchithanantham, S., Lachmann, H.J., Gillmore, J.D., Yong, K., ...Worthington, S. (2019). Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.. British Journal of Haematology, doi:10.1111/bjh.16122
Martone, R., Chacko, L., Bandera, F., Boldrini, M., Quarta, C., Cappelli, F., ...Fontana, M. (2019). Echocardiography C phenotype and independent predictors of prognosis in transthyretin cardiac amyloidosis.
Naharro, M.A., Kotecha, T., Chacko, L., Brown, J., Knight, D.S., Anderson, S., ...Xue, H. (2019). Fat water gadolinium enhancement imaging in myocarditis: shifting the goalpost.
Kotecha, T., Martinez-Naharro, A., Chacko, L., Brown, J., Knight, D., Anderson, S., ...Hawkins, P. (2019). FAT WATER IMAGING FOR SUB-EPICARDIAL GADOLINIUM: ENHANCING THE DIAGNOSIS OF MYOCARDITIS.
Liapis, K., Panagopoulou, P., Charitaki, E., Rowczenio, D., Gilbertson, J., Papathoma, A., ...Kastritis, E. (2019). Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant.. Amyloid, 1-2. doi:10.1080/13506129.2018.1562442
Hutchison, C.A., Cockwell, P., Moroz, V., Bradwell, A.R., Fifer, L., Gillmore, J.D., ...Winearls, C.G. (2019). High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.. Lancet Haematol, doi:10.1016/S2352-3026(19)30014-6
Martinez-Naharro, A., Gonzalez-Lopez, E., Corovic, A., Mirelis, J.G., Baksi, A.J., Moon, J.C., ...Fontana, M. (2019). High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. Journal of the American College of Cardiology, 73 (13), 1733-1734. doi:10.1016/j.jacc.2019.01.035
Naharro, M.A., Kotecha, T., Gonzalez-Lopez, E., Corovic, A., Anderson, S., Chacko, L., ...Moon, J.C. (2019). High prevalence of intracardiac thrombi in cardiac amyloidosis.
Kotecha, T., Gonzalez-Lopez, E., Corovic, A., Anderson, S., Chacko, L., Brown, J., ...Kellman, P. (2019). INTRACARDIAC THROMBI IN CARDIAC AMYLOIDOSIS, A COMMON FINDING.
Cohen, O.C., Sharpley, F., Gillmore, J., Lachmann, H., Sachchithanantham, S., Mahmood, S., ...Martinez-Naharro, A. (2019). Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis - a first report.
Kotecha, T., Martinez-Naharro, A., Brown, J., Little, C., Knight, D., Steriotis, A., ...Gillmore, J. (2019). MYOCARDIAL PERFUSION MAPPING IN CARDIAC AMYLOIDOSIS- UNEARTHING THE SPECTRUM FROM INFILTRATION TO ISCHAEMIA.
Chacko, L.L., Kotecha, T., Martinez, A., Brown, J., Little, C., Knight, D., ...Rakhit, R. (2019). Myocardial perfusion mapping in cardiac amyloidosis- Unearthing the spectrum from infiltration to ischaemia.
Martone, R., Chacko, L., Kotecha, T., Martinez-Naharro, A., Knight, D., Cappelli, F., ...Xue, H. (2019). Myocardial perfusion mapping in cardiac amyloidosis: extending the paradigm from infiltration to myocardial ischaemia.
Chacko, L.A., Kotecha, T., Martinez, A., Brown, J., Little, C., Knight, D., ...Moon, J. (2019). Myocardial perfusion mapping in cardiac amyloidosis: transformation from a disease of solely infiltration to myocardial ischaemia.
Lane, T., Fontana, M., Martinez-Naharro, A., Quarta, C.C., Whelan, C.J., Petrie, A., ...Rezk, T. (2019). Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.. Circulation, doi:10.1161/CIRCULATIONAHA.118.038169
Naharro, M.A., Kotecha, T., Chacko, L., Brown, J.D., Knight, D.S., Steriotis, A., ...Fontana, M. (2019). Oedema in amyloidosis: more than meets the eye.
Law, S., Lachmann, H., Rezk, T., Wechalekar, A., Gillmore, J., Motallebzadeh, R. (2019). Outcome of renal transplantation in systemic amyloidosis.
Law, S., Lachmann, H.J., Rezk, T., Wechalekar, A., Gillmore, J., Motallebzadeh, R. (2019). Outcome of renal transplantation in systemic amyloidosis.
Kapoor, M., Foiani, M., Heslegrave, A., Zetterberg, H., Lunn, M.P., Malaspina, A., ...Reilly, M.M. (2019). Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. Journal of the Peripheral Nervous System, doi:10.1111/jns.12350
Taylor, G.W., Gilbertson, J.A., Sayed, R., Blanco, A., Rendell, N.B., Rowczenio, D., ...Bass, P. (2019). Proteomic Analysis for the Diagnosis of Fibrinogen Aα-Chain Amyloidosis. Kidney International Reports, doi:10.1016/j.ekir.2019.04.007
Sharpley, F.A., Giles, H.V., Manwani, R., Mahmood, S., Sachchithanantham, S., Lachmann, H.J., ...Wechalekar, A.D. (2019). Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis.
Rowland, T.A., Gillmore, J., Bhandari, S. (2019). Regression of chronic kidney disease in a patient with AL amyloidosis: A case report. Clinical Nephrology, doi:10.5414/CN109676
Polydefkis, M., Gillmore, J., Dispenzieri, A., Chen, J., Sweetser, M.T., Vest, J., ...Kristen, A. (2019). Risk Factors for Mortality in Patients with Hereditary Transthyretin-Mediated Amyloidosis: An Analysis of APOLLO and Global Open Label Extension Studies.
Carr, A.S., Shah, S., Choi, D., Blake, J., Phadke, R., Gilbertson, J., ...Hawkins, P.N. (2019). Spinal Stenosis in Familial Transthyretin Amyloidosis.. J Neuromuscul Dis, doi:10.3233/JND-180348
Rezk, T., Gilbertson, J.A., Mangione, P.P., Rowczenio, D., Rendell, N., Canetti, D., ...Hawkins, P.N. (2019). The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. J Pathol Clin Res, doi:10.1002/cjp2.126
Leung, N., Bridoux, F., Batuman, V., Chaidos, A., Cockwell, P., D Agati, V.D., ...Gibbs, S. (2019). The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, doi:10.1038/s41581-018-0077-4
Leung, N., Bridoux, F., Batuman, V., Chaidos, A., Cockwell, P., D'Agati, V.D., ...Gibbs, S. (2019). The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (vol 15, pg 45, 2018). NATURE REVIEWS NEPHROLOGY, 15 (2), 121. doi:10.1038/s41581-018-0102-7
Cohen, O.C., Sharpley, F., Gillmore, J., Lachmann, H., Mahmood, S., Sachchithanantham, S., ...Hawkins, P. (2019). The UK Experience of Renal Transplantation in AL Amyloidosis.
Hawkins, P.N., Fontana, M., Gillmore, J.D. (2019). The UK National Amyloidosis Centre.. Eur Heart J, 40 (21), 1661-1664. doi:10.1093/eurheartj/ehz346
Papa, R., Gilbertson, J.A., Rendell, N., Wechalekar, A., Gillmore, J.D., Hawkins, P.N., Lachmann, H.J. (2019). TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT.

2018

Gillmore, J.D., Damy, T., Fontana, M., Hutchinson, M., Lachmann, H.J., Martinez-Naharro, A., ...Gonzalez-Lopez, E. (2018). A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 39 (30), 2799-2806. doi:10.1093/eurheartj/ehx589
Sharpley, F., Manwani, R., Mahmood, S., Sachchithanantham, S., Lachmann, H., Gillmore, J., ...Wechalekar, A.D. (2018). A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis.
Boldrini, M., Baggiano, A., Naharro, A.M., Kotecha, T., Rezk, T., Fayed, H., ...Gillmore, J. (2018). Accuracy of non contrast magnetic resonance for clinical diagnosis of cardiac amyloidosis - a 868 patient prospective study.
Kotecha, T., Martinez-Naharro, A., Gillmore, J.D., Hawkins, P.N., Fontana, M. (2018). Amyloidosis in the Era of Mass Spectrometry-Based Proteomics REPLY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72 (15), 1883. doi:10.1016/j.jacc.2018.08.1036
Martinez-Naharrro, A., Kotecha, T., Baggiano, A., Boldrini, M., Rezk, T., Knight, D.S., ...Mahmood, S. (2018). Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy.
Knight, D.S., Zumbo, G., Barcella, W., Steeden, J.A., Muthurangu, V., Martinez-Naharro, A., ...Kotecha, T. (2018). Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. JACC: Cardiovascular Imaging, doi:10.1016/j.jcmg.2018.02.016
Martinez-Naharro, A., Abdel-Gadir, A., Treibel, T.A., Zumbo, G., Knight, D.S., Rosmini, S., ...Whelan, C.J. (2018). CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 11 (1), 152-154. doi:10.1016/j.jcmg.2017.02.012
Rezk, T., Gilbertson, J.A., Rowczenio, D., Bass, P., Lachmann, H.J., Wechalekar, A.D., ...Whelan, C.J. (2018). Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 33 (2), 241-247. doi:10.1093/ndt/gfw375
Zumbo, G., Barton, S.V., Thompson, D., Sun, M., Abdel-Gadir, A., Treibel, T.A., ...Gillmore, J.D. (2018). Extracellular volume with bolus-only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time.. Journal of magnetic resonance imaging : JMRI, doi:10.1002/jmri.25907
Kotecha, T., Martinez-Naharro, A., Treibel, T.A., Francis, R., Nordin, S., Abdel-Gadir, A., ...Maestrini, V. (2018). Myocardial Edema and Prognosis in Amyloidosis. Journal of the American College of Cardiology, 71 (25), 2919-2931. doi:10.1016/j.jacc.2018.03.536
Martinez-Naharro, A., Kotecha, T., Norrington, K., Boldrini, M., Rezk, T., Quarta, C., ...Kellman, P. (2018). Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, doi:10.1016/j.jcmg.2018.02.006
Mangione, P.P., Verona, G., Corazza, A., Marcoux, J., Canetti, D., Giorgetti, S., ...Relini, A. (2018). Plasminogen activation triggers transthyretin amyloidogenesis in vitro. The Journal of biological chemistry, doi:10.1074/jbc.ra118.003990
Manwani, R., Foard, D., Mahmood, S., Sachchithanantham, S., Fontana, M., Whelan, C., ...Rezk, T. (2018). Prolonged progression free survival and time to next treatment are achievable outcomes in patients with systemic AL amyloidosis treated with novel agent chemotherapy - analysis of the ALchemy study.
Ross, J.C., Hutt, D.F., Burniston, M., Page, J., Steeden, J.A., Gillmore, J.D., ...Fontana, M. (2018). Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.. Amyloid, 25 (3), 203-210. doi:10.1080/13506129.2018.1520087
Borthwick, N.J., Lane, T., Moyo, N., Crook, A., Shim, J.M., Baines, I., ...Hanke, T. (2018). Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. PLOS ONE, 13 (5), doi:10.1371/journal.pone.0197299
Manwani, R., Foard, D., Mahmood, S., Sachchithanantham, S., Lane, T., Quarta, C., ...Gillmore, J.D. (2018). Rapid hematological responses improve outcomes in patients with very advanced (Stage IIIb) cardiac immunoglobulin light chain amyloidosis.. Haematologica, doi:10.3324/haematol.2017.178095
Richards, D.B., Cookson, L.M., Barton, S.V., Liefaard, L., Lane, T., Hutt, D.F., ...Gillmore, J.D. (2018). Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.. Science translational medicine, 10 (422), doi:10.1126/scitranslmed.aan3128
Manwani, R., Sachchithanantham, S., Mahmood, S., Foard, D., Sharpley, F., Rezk, T., ...Lachmann, H.J. (2018). Treatment of IgM-associated immunoglobulin light chain amyloidosis with Rituximab-Bendamustine.. Blood, doi:10.1182/blood-2018-04-846493
Martinez-Naharro, A., Kotecha, T., Baggiano, A., Boldrini, M., Rezk, T., Francis, R., ...Kellman, P. (2018). TREATMENT RESPONSE IN CARDIAC AL AMYLOIDOSIS ASSESSED BY CMR: FINDINGS AT 3 MONTHS, 6 MONTHS AND 1 YEAR POST-CHEMOTHERAPY.

2017

Fontana, M., Treibel, T.A., Martinez-Naharro, A., Rosmini, S., Kwong, R.Y., Gillmore, J.D., ...Moon, J.C. (2017). A case report in cardiovascular magnetic resonance: The contrast agent matters in amyloid. BMC Medical Imaging, 17 (1), doi:10.1186/s12880-016-0173-5
Carter, J.-.P., Foard, D., Rannigan, L., Aliaz, K., Mahmood, S., Sachchithanantham, S., ...Youngstein, T. (2017). A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year.
Raimondi, S., Porcari, R., Mangione, P.P., Verona, G., Marcoux, J., Giorgetti, S., ...Zanini, S. (2017). A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo.. Scientific reports, 7 46711. doi:10.1038/srep46711
Youngstein, T.A.-.B., Tsamados, S., Gilbertson, J.A., Smith, L., Hutt, D., Lane, T., ...Manwani, R. (2017). CARPAL TUNNEL BIOPSY AND BONE SCINTIGRAPHY USING THE TECHNETIUM-3,3-DIPHOSPHONO-1,2-PROPANODICARBOXYLIC ACID (99M) (TC-DPD) TRACER CAN IDENTIFY CLINICALLY SILENT CARDIAC AMYLOIDOSIS AT A POTENTIALLY TREATABLE STAGE.
Youngstein, T., Gilbertson, J.A., Hutt, D.F., Coyne, M.R.E., Rezk, T., Manwani, R., ...Gillmore, J.D. (2017). Carpal Tunnel Biopsy identifying Transthyretin Amyloidosis.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.40162
Lane, T., Pinney, J.H., Gilbertson, J.A., Hutt, D.F., Rowczenio, D.M., Mahmood, S., ...Quarta, C.C. (2017). Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 1-5. doi:10.1080/13506129.2017.1342235
Manwani, R., Foard, D., Mahmood, S., Sachchithanantham, S., Fontana, M., Whelan, C., ...Hawkins, P. (2017). Clinical Profiles and Outcomes in 1203 Newly Diagnosed Patients With Systemic AL Amyloidosis - First Analysis of the ALChemy Study..
Norrington, K., Martinez-Naharro, A., Kotecha, T., Francis, R., Hutt, D.F., Rezk, T., ...Knight, D. (2017). CLINICAL UTILITY OF T1 MAPPING IN CARDIAC ATTR AMYLOIDOSIS - DIAGNOSTIC PERFORMANCE AND PROGNOSTIC CAPABILITY.
Martinez-Naharro, A., Abdel-Gadir, A., Treibel, T.A., Zumbo, G., Knight, D.S., Rosmini, S., ...Whelan, C.J. (2017). DEMONSTRATION OF CARDIAC AL AMYLOIDOSIS REGRESSION AFTER SUCCESFUL CHEMOTHERAPY. A CMR STUDY.
Quarta, C.C., Gonzalez-Lopez, E., Gilbertson, J.A., Botcher, N., Rowczenio, D., Petrie, A., ...Sachchithanantham, S. (2017). Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. EUROPEAN HEART JOURNAL, 38 (24), 1905-1908. doi:10.1093/eurheartj/ehx047
Youngstein, T.A.-.B., Lane, T., Gilbertson, J., Pinney, J., Rezk, T., Manwani, R., ...Sachchithanantham, S. (2017). DISEASE-MODIFYING TREATMENT REGIMENS HAVE BEEN INSUFFICIENT TO REDUCE THE INCIDENCE OF SYSTEMIC AA AMYLOIDOSIS ASSOCIATED WITH RHEUMATOID ARTHRITIS IN CONTRAST TO A SIGNIFICANT REDUCTION IN THOSE WITH JUVENILE IDIOPATHIC ARTHRITIS.
Sachchithanantham, S., Berlanga, O., Alvi, A., Mahmood, S.A., Lachmann, H.J., Gillmore, J.D., ...Wechalekar, A.D. (2017). Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis. British Journal of Haematology, doi:10.1111/bjh.14908
Mangione, P.P., Mazza, G., Gilbertson, J.A., Rendell, N.B., Canetti, D., Giorgetti, S., ...Raimondi, S. (2017). Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. Journal of proteomics, doi:10.1016/j.jprot.2017.06.016
Verona, V.L., Mangione, P.P., Raimondi, S., Giorgetti, S., Faravelli, G., Porcari, R., ...Pepys, M.B. (2017). Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. Scientific Reports, doi:10.1038/s41598-017-00338-x
Shafi, A.M.A., Whelan, C., Fontana, M., Quarta, C., Mahmood, S., Lachmann, H., ...Wechalekar, A. (2017). Length of Hospital Stay is an Independent Predictor of Overall Survival in Patients with systemic AL Amyloidosis.
Treibel, T.A., Gilbertson, J.A., Taylor, G.W., Rendell, N.B., Fontana, M., Gillmore, J.D., ...Moon, J.C. (2017). Letter by Treibel et al Regarding Article, "Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic Severity of Aortic Stenosis: Is Valvular Fibrosis the Explanation?". CIRCULATION RESEARCH, 120 (5), E24-E25. doi:10.1161/CIRCRESAHA.116.310475
Martinez-Naharro, A. (2017). Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, doi:10.1016/j.jacc.2017.05.053
Yeung, J., Sivarajan, S., Treibel, T.A., Rosmini, S., Fontana, M., Gillmore, J.D., ...Taylor, S.A. (2017). Measurement of liver and spleen interstitial volume in patients with systemic amyloid light-chain amyloidosis using equilibrium contrast CT. Abdominal Radiology, 1-6. doi:10.1007/s00261-017-1194-4
Canetti, D., Rendell, N.B., Di Vagno, L., Gilbertson, J.A., Rowczenio, D., Rezk, T., ...Mangione, P.P. (2017). Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. Amyloid, 1-9. doi:10.1080/13506129.2017.1385452
Rowczenio, D.M., Pathak, S., Arostegui, J.I., Mensa-Vilaro, A., Omoyinmi, E., Brogan, P., ...Trojer, H. (2017). Molecular genetic investigation, clinical features and response to treatment in 21 patients with Schnitzler's syndrome.. Blood, doi:10.1182/blood-2017-10-810366
Kotecha, T., Martinez-Naharro, A., Treibel, T.A., Francis, R., Nordin, S., Abdel-Gadir, A., ...Maestrini, V. (2017). MULTIPARAMETRIC MAPPING TO UNDERSTAND PATHOPHYSIOLOGY IN CARDIAC AMYLOIDOSIS.
Phillips, E.H., Nash, S., Adedayo, T., Whelan, C.J., Fontana, M., Mahmood, S., ...Clifton-Hadley, L. (2017). Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study. Amyloid, 1-3. doi:10.1080/13506129.2017.1385453
Hutt, D.F., Fontana, M., Burniston, M., Quigley, A.M., Petrie, A., Ross, J.C., ...Lachmann, H.J. (2017). Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal - Cardiovascular Imaging, doi:10.1093/ehjci/jew325
Manwani, R., Foard, D., Mahmood, S., Sachchithanantham, S., Fontana, M., Whelan, C., ...Gillmore, J. (2017). Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study.
Rezk, T., Lachmann, H.J., Fontana, M., Sachchithanantham, S., Mahmood, S., Petrie, A., ...Lane, T. (2017). Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.. Kidney international, doi:10.1016/j.kint.2017.05.004
Rowczenio, D., Stensland, M., de Souza, G.A., Strøm, E.H., Gilbertson, J.A., Taylor, G., ...Lachmann, H.J. (2017). Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein. Kidney International Reports, 2 (3), 461-469. doi:10.1016/j.ekir.2016.11.005
Rezk, T., Whelan, C.J., Lachmann, H.J., Fontana, M., Sachchithanantham, S., Mahmood, S., ...Youngstein, T. (2017). Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. British Journal of Haematology, doi:10.1111/bjh.14747
Martinez-Naharro, A., Knight, D.S., Kotecha, T., Francis, R., Zumbo, G., Treibel, T.A., ...Ugander, M. (2017). ROUTINE IDENTIFICATION OF HYPOPERFUSION IN CARDIAC AMYLOIDOSIS BY MYOCARDIAL BLOOD FLOW MAPPING.
Manwani, R., Hegenbart, U., Foard, D., Mahmood, S., Sachchithanantham, S., Yong, K., ...Fontana, M. (2017). Safety and Efficacy of Deferred Autologous Stem Cell Transplantation in Patients with Systemic AL Amyloidosis with Significant Cardiac Involvement at Presentation.
Lane, T., Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N., Lachmann, H.J. (2017). Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.. Amyloid, 1-5. doi:10.1080/13506129.2017.1352503
Flatman, K., Foard, D., Pyart, E., Hughes, G., Gaudia, R., Kearney, C., ...Caringal-Galima, J. (2017). Six-minute walk test (6MWT) in AL amyloidosis - baseline and 12-month follow-up after chemotherapy.
Martinez-Naharro, A., Treibel, T.A., Abdel-Gadir, A., Bulluck, H., Zumbo, G., Knight, D.S., ...Rezk, T. (2017). SPECTRUM AND SIGNIFICANCE OF CMR FINDINGS IN CARDIAC TRANSTHYRETIN AMYLOIDOSIS.

2016

Tougaard, B.G., Pedersen, K.V., Palmelund Krag, S.R., Gilbertson, J.A., Rowczenio, D., Gillmore, J.D., Birn, H. (2016). A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype.. European Journal of Medical Genetics, doi:10.1016/j.ejmg.2016.05.015
Dungu, J.N., Papadopoulou, S.A., Wykes, K., Mahmood, I., Marshall, J., Valencia, O., ...Hawkins, P.N. (2016). Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis.. Circulation. Heart failure, 9 (9), doi:10.1161/CIRCHEARTFAILURE.116.003352
Rowczenio, D.M., Iancu, D.S., Trojer, H., Gilbertson, J.A., Gillmore, J.D., Wechalekar, A.D., ...Lane, T. (2016). Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration.. Rheumatology (Oxford, England),
Zheng, J., Hutt, D., Gillmore, J., Whelan, C., Quarta, C., Fontana, M., ...Wechalekar, A. (2016). CARDIAC UPTAKE IN AL AMYLOIDOSIS OF 99MTC-DPD AS A NOVEL MARKER OF POOR PROGNOSIS IN SYSTEMIC AL AMYLOIDOSIS.
Youngstein, T.A.B., Gillott, E., Gilbertson, J., Boniface, K., Hutt, D., Lane, T., ...Lachmann, H. (2016). CARPAL TUNNEL BIOPSY AS A DIAGNOSTIC TOOL TO IDENTIFY EARLY CASES OF CARDIAC AMYLOIDOSIS: RESULTS OF A PILOT STUDY.
Wechalekar, A., Foard, D., Whelan, C., Fontana, M., Lane, T., Quarta, C., ...Hawkins, P.N. (2016). Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study.
Mahmood, S., Wassef, N.L., Salter, S.J., Sachchithanantham, S., Lane, T., Foard, D., ...Hawkins, P.N. (2016). Comparison of Free Light Chain Assays Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 146 (1), 78-85. doi:10.1093/ajcp/aqw079
Valleix, S., Verona, G., Jourde-Chiche, N., Nedelec, B., Mangione, P.P., Bridoux, F., ...Lhomme, M. (2016). D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. NATURE COMMUNICATIONS, 7 doi:10.1038/ncomms10353
Sachchithanantham, S., Roussel, M., Palladini, G., Klersy, C., Mahmood, S., Venner, C.P., ...Hawkins, P.N. (2016). European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. JOURNAL OF CLINICAL ONCOLOGY, 34 (17), 2037-+. doi:10.1200/JCO.2015.63.3123
Cook, M., Hutchison, C., Fifer, L., Gillmore, J., Heyne, N., Weisel, K., ...Cockwell, P. (2016). HIGH CUT-OFF HAEMODIALYSIS (HCO-HD) DOES NOT IMPROVE OUTCOMES IN MYELOMA CAST NEPHROPATHY: RESULTS OF EUROPEAN TRIAL OF FREE LIGHT CHAIN REMOVAL BY EXTENDED HAEMODIALYSIS IN CAST NEPHROPATHY (EULITE).
Mahmood, S., Sovani, M., Smith, P., George, L., Quarta, C.C., Sachchithanantham, S., ...Gillmore, J.D. (2016). High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 32 191-197. doi:10.1016/j.sleep.2016.11.021
Gillmore, J.D., Maurer, M.S., Falk, R.H., Merlini, G., Damy, T., Dispenzieri, A., ...Grogan, M. (2016). Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. CIRCULATION, 133 (24), 2404-+. doi:10.1161/CIRCULATIONAHA.116.021612
Treibel, T.A., Fontana, M., Gilbertson, J.A., Castelletti, S., White, S.K., Scully, P.R., ...Whelan, C.J. (2016). Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circulation: Cardiovascular Imaging, 9 (8), doi:10.1161/CIRCIMAGING.116.005066
Martinez-Naharro, A., Abdel-Gadir, A., Treibel, T.A., Zumbo, G., Knight, D.S., Rosmini, S., ...Whelan, C.J. (2016). Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance.
Fontana, M., Pica, S., Reant, P., Abdel-Gadir, A., Treibel, T.A., Banypersad, S.M., ...Bulluck, H. (2016). Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis". CIRCULATION, 133 (12), E450-E451. doi:10.1161/CIRCULATIONAHA.116.021162
Ruberg, F.L., Fontana, M., Gillmore, J.D. (2016). Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?. Journal of the American College of Cardiology, 68 (22), 2493-2494. doi:10.1016/j.jacc.2016.07.786

2015

Gilbertson, J.A., Theis, J.D., Vrana, J.A., Lachmann, H., Wechalekar, A., Whelan, C., ...Gillmore, J.D. (2015). A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. JOURNAL OF CLINICAL PATHOLOGY, 68 (4), 314-317. doi:10.1136/jclinpath-2014-202722
Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., ...Wechalekar, A.D. (2015). A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. BLOOD, 126 (5), 612-615. doi:10.1182/blood-2015-01-620302
Marcoux, J., Mangione, P.P., Porcari, R., Degiacomi, M.T., Verona, G., Taylor, G.W., ...Benesch, J.L. (2015). A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med, 7 (10), 1337-1349. doi:10.15252/emmm.201505357
Jimenez-Zepeda, V.H., Bahlis, N.J., Gilbertson, J., Rendell, N., Porcari, R., Lachmann, H.J., ...Rowczenio, D.M. (2015). A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 22 (1), 26-30. doi:10.3109/13506129.2014.987377
Gillmore, J.D., Falk, R., Maurer, M., Hanna, M., Karsten, V., Penz, C., ...Hawkins, P. (2015). A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS.
Sevillano, B., Wechalekar, A., Foard, D., Whelan, C., Fontana, M., Quarta, C., ...Hawkins, P.N. (2015). A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis.
Sayed, R.H., Rogers, D., Khan, F., Wechalekar, A.D., Lachmann, H.J., Fontana, M., ...Hawkins, P.N. (2015). A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.. EUROPEAN HEART JOURNAL, 36 (18), 1098-1105. doi:10.1093/eurheartj/ehu506
Carr, A.S., Pelayo-Negro, A.L., Evans, M.R.B., Laura, M., Blake, J., Stancanelli, C., ...Gillmore, J.D. (2015). A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 87 (6), 620-627. doi:10.1136/jnnp-2015-310907
Carr, A.S., Pelayo-Negro, A.L., Evans, M.R.B., Laurà, M., Blake, J., Stancanelli, C., ...Gillmore, J.D. (2015). A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. Journal of Neurology, Neurosurgery and Psychiatry, 87 (6), 620-627. doi:10.1136/jnnp-2015-310907
Vonberg, F.W., Gilbertson, J.A., Rowczenio, D., Hutt, D.F., Rendell, N., Taylor, G., ...Gillmore, J.D. (2015). Amyloid cardiomyopathy associated with a novel apolipoprotein A-I Q172P variant. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 22 (4), 252-253. doi:10.3109/13506129.2015.1077217
Sachchithanantham, S., Offer, M., Venner, C., Mahmood, S.A., Foard, D., Rannigan, L., ...Hawkins, P.N. (2015). Clinical profile and treatment outcome of older (> 75 years) patients with systemic AL amyloidosis. HAEMATOLOGICA, 100 (11), 1469-1476. doi:10.3324/haematol.2015.128025
Rowczenio, D., Trojer, H., Baginska, A., Gillmore, J., Wechalekar, A., Hawkins, P., Lachmann, H. (2015). Clinical symptoms and molecular investigations in 13 patients with Schnitzler syndrome identified at the single UK centre. Pediatric Rheumatology, doi:10.1186/1546-0096-13-S1-P38
Rowczenio, D., Iancu, D., Trojer, H., Gilbertson, J., Gillmore, J., Wechalekar, A., ...Lane, T. (2015). Deletion in MEFV resulting in the loss of p.M694 residue as the cause of autosomal dominant familial Mediterranean fever in North Western European Caucasians - a case series and genetic exploration.
Fontana, M., Banypersad, S.M., Treibel, T.A., Abdel-Gadir, A., Maestrini, V., Lane, T., ...Whelan, C.J. (2015). Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. RADIOLOGY, 277 (2), 388-397. doi:10.1148/radiol.2015141744
Quarta, C.C., Ozer, S., Whelan, C.J., Fontana, M., Rowczenio, D.M., Gilbertson, J.A., ...Gillmore, J.D. (2015). Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study. Orphanet Journal of Rare Diseases, 10 1-2. doi:10.1186/1750-1172-10-S1-O23
Pepys, M.B., Cookson, L.M., Barton, S.V., Berges, A.C., Lane, T., Hutt, D., ...Wechalekar, A. (2015). Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP).
Mahmood, S., Riddle, A., Sachchithanantham, S., Lane, T., Foard, D., Sayed, R., ...Youngstein, C. (2015). ELEVATED FACTOR VIII LEVELS CARRY A POOR OVERALL SURVIVAL IN NEWLY DIAGNOSED SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS PATIENTS.
Lane, T., Rowczenio, D.M., Gilbertson, J.A., Gillmore, J.D., Wechalekar, A.D., Hawkins, P.N., Lachmann, H.J. (2015). Empirical use of anakinra in AA amyloidosis of uncertain aetiology. Pediatric Rheumatology, 13 (Supp 1), doi:10.1186/1546-0096-13-S1-O70
Treibel, T.A., Bandula, S., Fontana, M., White, S.K., Gilbertson, J.A., Herrey, A.S., ...Taylor, S.A. (2015). Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis.. Journal of Cardiovascular Computer Tomography, 9 (6), 585-592. doi:10.1016/j.jcct.2015.07.001
Fontana, M., Abdel-Gadir, A., Treibel, T.A., Gillmore, J.D., Hawkins, P.N., Moon, J.C., Manisty, C.H. (2015). Familial amyloid polyneuropathy: the importance of cardiac involvement. EUROPEAN JOURNAL OF HEART FAILURE, 17 23.
Gillmore, J.D., Wechalekar, A., Bird, J., Cavenagh, J., Hawkins, S., Kazmi, M., ...BCSH, C.o.m.m.i.t.t.e.e. (2015). Guidelines on the diagnosis and investigation of AL amyloidosis.. BRITISH JOURNAL OF HAEMATOLOGY, 168 (2), 207-218. doi:10.1111/bjh.13156
Wechalekar, A.D., Gillmore, J.D., Bird, J., Cavenagh, J., Hawkins, S., Kazmi, M., ...Pratt, G. (2015). Guidelines on the management of AL amyloidosis. British Journal of Haematology, 168 (2), 186-206. doi:10.1111/bjh.13155
Sachchithanantham, S., Berlanga, O., Alvi, A., Wassef, N., Mahmood, S., Sayeed, R., ...Hawkins, P. (2015). HEAVY/LIGHT CHAIN IMMUNOPARESIS AS A NOVEL MARKER OF POOR OUTCOMES IN SYSTEMIC AL AMYLOIDOSIS.
Werner, R.A., Maya, Y., Yamane, T., Rischpler, C., Fukushima, K., Chen, X., ...Thorn, S. (2015). Moderated Poster Session 4: Monday 4 May 2015, 15:30-16:30Room: Moderated Poster Area.. European heart journal cardiovascular Imaging, 16 Suppl 1 i35-i37.
Sayed, R.H., Wechalekar, A.D., Gilbertson, J.A., Bass, P., Mahmood, S., Sachchithanantham, S., ...Lachmann, H.J. (2015). Natural history and outcome of light chain deposition disease. BLOOD, 126 (26), 2805-2810. doi:10.1182/blood-2015-07-658872
Mahmood, S., Bridoux, F., Venner, C.P., Sachchithanantham, S., Gilbertson, J.A., Rowczenio, D., ...Fontana, M. (2015). Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. LANCET HAEMATOLOGY, 2 (6), E241-E250. doi:10.1016/S2352-3026(15)00068-X
McColgan, P., Viegas, S., Gandhi, S., Bull, K., Tudor, R., Sheikh, F., ...Gillmore, J.D. (2015). Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.. J Neurol, 262 (1), 228-234. doi:10.1007/s00415-014-7594-2
Wechalekar, A., Whelan, C., Lachmann, H., Fontana, M., Mahmood, S., Gillmore, J.D., Hawkins, P.N. (2015). Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study.
Gillmore, J.D., Falk, R.H., Maurer, M.S., Hanna, M., Karsten, V., Vest, J., ...Hawkins, P.N. (2015). Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis. Orphanet Journal of Rare Diseases, 10 1-2. doi:10.1186/1750-1172-10-S1-O21
Fontana, M., Pica, S., Reant, P., Abdel-Gadir, A., Treibel, T.A., Banypersad, S.M., ...Bulluck, H. (2015). Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 132 (16), 1570-1579. doi:10.1161/CIRCULATIONAHA.115.016567
Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N. (2015). Systemic amyloidosis. Lancet (London, England), 387 (10038), 2641-2654. doi:10.1016/S0140-6736(15)01274-X
Banypersad, S.M., Fontana, M., Maestrini, V., Sado, D.M., Captur, G., Petrie, A., ...Gillmore, J.D. (2015). T1 mapping and survival in systemic light-chain amyloidosis.. Eur Heart J, 36 (4), 244-251. doi:10.1093/eurheartj/ehu444
Dubrey, S., Ackermann, E., Gillmore, J. (2015). The transthyretin amyloidoses: Advances in therapy. Postgraduate Medical Journal, 91 (1078), 439-448. doi:10.1136/postgradmedj-2014-133224
Dubrey, S., Ackermann, E., Gillmore, J. (2015). The transthyretin amyloidoses: advances in therapy. POSTGRADUATE MEDICAL JOURNAL, 91 (1078), 439-448. doi:10.1136/postgradmedj-2014-133224
Lane, T., Gillmore, J.D., Wechalekar, A.D., Hawkins, P.N., Lachmann, H.J. (2015). Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 33 (6), S46-S53.
Lane, T., Gillmore, J.D., Wechalekar, A.D., Hawkins, P.N., Lachmann, H.J. (2015). Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.. Clinical and experimental rheumatology, 33 (6 Suppl 94), S46-S53.
Richards, D.B., Cookson, L.M., Berges, A.C., Barton, S.V., Lane, T., Ritter, J.M., ...Gillmore, J.D. (2015). Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. NEW ENGLAND JOURNAL OF MEDICINE, 373 (12), 1106-1114. doi:10.1056/NEJMoa1504942
Gillmore, J.D., Hawkins, P.N. (2015). To the editor. New England Journal of Medicine, 372 (18), 1769-. doi:10.1056/NEJMc1503222
Carr, A.S., Pelayo-Negro, A.L., Jaunmuktane, Z., Scalco, R.S., Hutt, D., Evans, M.R.B., ...Blake, J. (2015). Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. NEUROMUSCULAR DISORDERS, 25 (6), 511-515. doi:10.1016/j.nmd.2015.02.001
Ruberg, F.L., Berk, J.L., Semigan, M.J. (2015). V122I Transthyretin Variant in Elderly Black Americans. NEW ENGLAND JOURNAL OF MEDICINE, 372 (18), 1768. doi:10.1056/NEJMc1503222

2014

Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J.D., Foli, A., Hawkins, P.N., ...Wechalekar, A.D. (2014). A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis.
Wechalekar, A., Whelan, C., Sachchithanantham, S., Fontana, M., Mahmood, S., Foard, D., ...Hawkins, P.N. (2014). A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort.
Venner, C.P., Gillmore, J.D., Sachchithanantham, S., Mahmood, S., Lane, T., Foard, D., ...Whelan, C.J. (2014). A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis.. LEUKEMIA, 28 (12), 2304-2310. doi:10.1038/leu.2014.218
Sachchithanantham, S., Mahmood, S., Sayed, R., Patel, K., Gillmore, J., Lachmann, H., ...Hawkins, P.N. (2014). A PROFILE OF 140 LONG-TERM SURVIVORS WITH SYSTEMIC AL AMYLOIDOSIS.
Dubrey, S.W., Ghonim, S., Gillmore, J.D. (2014). A white man with a very African form of hereditary amyloid cardiomyopathy.. BRITISH JOURNAL OF HOSPITAL MEDICINE, 75 (10), 592-593. doi:10.12968/hmed.2014.75.10.592
Gillmore, J.D., Lachmann, H.J. (2014). Amyloidosis. In Practical Nephrology. (pp. 311-322). .
Fontana, M., Pica, S., Reant, P., Abdel-Gadir, A., Treibel, T.A., Banypersad, S.M., ...Whelan, C.J. (2014). Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A 242 Patient Prospective Study.
Wechalekar, A., Foard, D., Rannagan, L., Lane, T., Sachachtanatham, S., Mahmood, S., ...Hawkins, P. (2014). CHARACTERISTICS AND OUTCOMES OF 714 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS -ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY (ALCHEMY STUDY).
Rowczenio, D., Tennent, G.A., Gilbertson, J., Lachmann, H.J., Hutt, D.F., Bybee, A., ...Gillmore, J.D. (2014). Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis.. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 21 (4), 276-281. doi:10.3109/13506129.2014.973105
Dungu, J.N., Valencia, O., Pinney, J.H., Gibbs, S.D.J., Rowczenio, D., Gilbertson, J.A., ...Whelan, C.J. (2014). CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC-CARDIOVASCULAR IMAGING, 7 (2), 133-142. doi:10.1016/j.jcmg.2013.08.015
Jaccard, A., Comenzo, R.L., Hari, P., Hawkins, P.N., Roussel, M., Morel, P., ...Mohty, D. (2014). Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).. HAEMATOLOGICA, 99 (9), 1479-1485. doi:10.3324/haematol.2014.104109
Boyle, E.M., Walker, B.A., Rowczienio, D., Wardell, C.P., Murison, A., Mikulasova, A., ...Gillmore, J.D. (2014). Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis. BLOOD, 124 (21),
Patel, K.S., Fontana, M., Sachchithanantham, S., Sayed, R., Wechalekar, A.D., Lachmann, H.J., ...Gillmore, J.D. (2014). Heterogeneity of Electrocardiographic Findings in Cardiac Transthyretin (ATTR) Amyloidosis and Impact on Survival.
Mahmood, S., George, L., Sovani, M., Smith, P., Hawkins, P., Sachchithanantham, S., ...Sayed, R. (2014). High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis.
Mahmood, S., George, L., Sovani, M., Smith, P., Hawkins, P., Sachchithanantham, S., ...Sayed, R. (2014). High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis.
Lane, T., Wassef, N., Poole, S., Mistry, Y., Lachmann, H.J., Gillmore, J.D., ...Pepys, M.B. (2014). Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circulation Research, 114 (4), 672-676. doi:10.1161/CIRCRESAHA.114.302770
Lane, T., Wassef, N., Poole, S., Mistry, Y., Lachmann, H.J., Gillmore, J.D., ...Pepys, M.B. (2014). Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers.. CIRCULATION RESEARCH, 114 (4), 672-676. doi:10.1161/CIRCRESAHA.114.302770
Mahmood, S., Venner, C.P., Sachchithanantham, S., Lane, T., Rannigan, L., Foard, D., ...Lachmann, H.J. (2014). Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. British Journal of Haematology, 166 (6), 842-848. doi:10.1111/bjh.12973
Mahmood, S., Venner, C.P., Sachchithanantham, S., Lane, T., Rannigan, L., Foard, D., ...Lachmann, H.J. (2014). Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.. BRITISH JOURNAL OF HAEMATOLOGY, 166 (6), 842-848. doi:10.1111/bjh.12973
Patel, K.S., Hawkins, P.N., Whelan, C.J., Gillmore, J.D. (2014). Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.. BMJ Case Reports, 2014 doi:10.1136/bcr-2014-206600
Stringaris, K., Sayed, R., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N., Wechelaker, A. (2014). Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD).
Sayed, R.H., Gilbertson, J.A., Hutt, D.F., Lachmann, H.J., Hawkins, P.N., Bass, P., Gillmore, J.D. (2014). Misdiagnosing renal amyloidosis as minimal change disease.. NEPHROLOGY DIALYSIS TRANSPLANTATION, 29 (11), 2120-2126. doi:10.1093/ndt/gfu242
Fontana, M., Banypersad, S.M., Treibel, T.A., Maestrini, V., Sado, D.M., White, S.K., ...Robson, M.D. (2014). Native T1 mapping in transthyretin amyloidosis. JACC: Cardiovascular Imaging, 7 (2), 157-165. doi:10.1016/j.jcmg.2013.10.008
Fontana, M., Banypersad, S.M., Treibel, T.A., Maestrini, V., Sado, D.M., White, S.K., ...Robson, M.D. (2014). Native T1 mapping in transthyretin amyloidosis.. JACC-CARDIOVASCULAR IMAGING, 7 (2), 157-165. doi:10.1016/j.jcmg.2013.10.008
Efebera, Y.A., Sturm, A., Baack, E.C., Hofmeister, C.C., Satoskar, A., Nadasdy, T., ...Hawkins, P.N. (2014). Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 21 (2), 110-112. doi:10.3109/13506129.2014.891502
Rowczenio, D.M., Noor, I., Gillmore, J.D., Lachmann, H.J., Whelan, C., Hawkins, P.N., ...Wechalekar, A.D. (2014). Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Human Mutation, 35 (9), doi:10.1002/humu.22619
Rowczenio, D.M., Noor, I., Gillmore, J.D., Lachmann, H.J., Whelan, C., Hawkins, P.N., ...Wechalekar, A.D. (2014). Online registry for mutations in hereditary amyloidosis including nomenclature recommendations.. HUMAN MUTATION, 35 (9), E2403-E2412. doi:10.1002/humu.22619
Mangione, P.P., Porcari, R., Gillmore, J.D., Pucci, P., Monti, M., Porcari, M., ...Serpell, L.C. (2014). Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 111 (4), 1539-1544. doi:10.1073/pnas.1317488111
Venner, C.P., Gillmore, J.D., Sachchithanantham, S., Mahmood, S., Lane, T., Foard, D., ...Pinney, J.H. (2014). Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.. HAEMATOLOGICA, 99 (12), doi:10.3324/haematol.2014.108191
Sachchithanantham, S., de Tute, R.M., Baginska, A., Parrish, C., Mahmood, S., Rawstron, A., ...Owen, R.G. (2014). The Prognostic Significance of Phenotypically `Normal' Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma.
Mahmood, S., Gilbertson, J.A., Rendell, N., Whelan, C.J., Lachmann, H.J., Wechalekar, A.D., ...Gillmore, J.D. (2014). Two types of amyloid in a single heart.. BLOOD, 124 (19), 3025-3027. doi:10.1182/blood-2014-06-580720
Hutt, D.F., Quigley, A.-.M., Page, J., Hall, M.L., Burniston, M., Gopaul, D., ...Gillmore, J.D. (2014). Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 15 (11), 1289-1298. doi:10.1093/ehjci/jeu107
Owen-Casey, M.P., Sim, R., Cook, H.T., Roufosse, C.A., Gillmore, J.D., Gilbertson, J.A., ...Howie, A.J. (2014). Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies. Journal of Clinical Pathology, 67 (8), 661-666. doi:10.1136/jclinpath-2014-202231
Owen-Casey, M.P., Sim, R., Cook, H.T., Roufosse, C.A., Gillmore, J.D., Gilbertson, J.A., ...Howie, A.J. (2014). Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies.. J Clin Pathol, 67 (8), 661-666. doi:10.1136/jclinpath-2014-202231

2013

Lachmann, H.J., Gillmore, J.D., Wechalekar, A.D., Gibbs, S.D., Pinney, J.H., Rowczenio, D.M., ...Banypersad, S.M. (2013). A 20 YEAR SINGLE CENTRE EXPERIENCE OF AA AMYLOIDOSIS DEMONSTRATING CHANGES IN ITS EPIDEMIOLOGY. ANNALS OF THE RHEUMATIC DISEASES, 71 283-284. doi:10.1136/annrheumdis-2012-eular.2344
Wechalekar, A.D., Schonland, S.O., Kastritis, E., Gillmore, J.D., Dimopoulos, M.A., Lane, T., ...Rannigan, L. (2013). A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. BLOOD, 121 (17), 3420-3427. doi:10.1182/blood-2012-12-473066
Sattianayagam, P.T., Lane, T., Fox, Z., Petrie, A., Gibbs, S.D.J., Pinney, J.H., ...Lachmann, H.J. (2013). A prospective study of nutritional status in immunoglobulin light chain amyloidosis.. HAEMATOLOGICA, 98 (1), 136-140. doi:10.3324/haematol.2012.070359
Lane, T., Loeffler, J.M., Rowczenio, D.M., Gilbertson, J.A., Bybee, A., Russell, T.L., ...Lachmann, H.J. (2013). AA amyloidosis complicating the hereditary periodic fever syndromes. ARTHRITIS AND RHEUMATISM, 65 (4), 1116-1121. doi:10.1002/art.37827
Sachchithanantham, S., Mahmood, S., Sayed, R., Patel, K., Fontana, M., Lane, T., ...Lachmann, H. (2013). Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis.
Lane, T., Loeffler, J.M., Rowczenio, D.M., Gilbertson, J.A., Bybee, A., Russell, T.L., ...Lachmann, H.J. (2013). Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. ARTHRITIS AND RHEUMATISM, 65 (4), 1116-1121. doi:10.1002/art.37827
Patel, K.S., Pinney, J.H., Sachchithanantham, S., Mahmood, S., Wechalekar, A.D., Lachmann, H.J., ...Whelan, C.J. (2013). Cardiac transthyretin (ATTR) amyloidosis - clinical and echocardiographic findings from the largest single cohort worldwide.
Rowczenio, D.M., Trojer, H., Russell, T., Baginska, A., Lane, T., Stewart, N.M., ...Mikoluc, B. (2013). Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature.. Arthritis Research & Therapy, 15 doi:10.1186/ar4171
Roussel, M., Sachchithanantham, S., Gibbs, S.D.J., Venner, C.P., Pinney, J.H., Gillmore, J.D., ...Wechalekar, A.D. (2013). Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis. British Journal of Haematology, 162 (6), 856-858. doi:10.1111/bjh.12433
Roussel, M., Sachchithanantham, S., Gibbs, S.D.J., Venner, C.P., Pinney, J.H., Gillmore, J.D., ...Wechalekar, A.D. (2013). Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 162 (6), 856-858. doi:10.1111/bjh.12433
Mahmood, S., Wassef, N., Sachchithanantham, S., Rannigan, L., Taylor, W., Lane, T., ...Pinney, J. (2013). COMPARISON OF FREELITE AND N LATEX SERUM FREE LIGHT CHAIN ASSAYS AND PREDICTING SURVIVAL.
Siddique, N., Gillmore, J.D., Sattianayagam, P.T. (2013). Decreasing incidence of AA amyloidosis in Spain.. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 43 (12), 1372. doi:10.1111/eci.12157
Walker, B.A., Rowczienio, D., Boyle, E.M., Wardell, C.P., Sachchithanantham, S., Baginska, A., ...Hawkins, P.N. (2013). Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis.
Sattianayagam, P.T., Gillmore, J.D., Pinney, J.H., Gibbs, S.D.J., Wechalekar, A.D., Gilbertson, J.A., ...Lachmann, H.J. (2013). Inflammatory bowel disease and systemic AA amyloidosis. Digestive Diseases and Sciences, 58 (6), 1689-1697. doi:10.1007/s10620-012-2549-x
Sattianayagam, P.T., Gillmore, J.D., Pinney, J.H., Gibbs, S.D.J., Wechalekar, A.D., Gilbertson, J.A., ...Lachmann, H.J. (2013). Inflammatory bowel disease and systemic AA amyloidosis.. DIGESTIVE DISEASES AND SCIENCES, 58 (6), 1689-1697. doi:10.1007/s10620-012-2549-x
Mahmood, A.S., Sachchithanantham, S., Venner, C.V., Lane, T., Rannigan, L., Foard, D., ...Hawkins, P.N. (2013). Laryngo-tracheobronchial amyloidosis - a 30 year institutional experience. BRITISH JOURNAL OF HAEMATOLOGY, 161 51-52.
Banypersad, S.M., Fontana, M., Sado, D., Pinney, J., Mahmood, S., Sachchithanantham, S., ...Gillmore, J. (2013). Myocardial Extracellular Volume Fraction and Survival in Systemic AL Amyloidosis.
Gillmore, J.D., Hawkins, P.N. (2013). Pathophysiology and treatment of systemic amyloidosis. Nature Reviews Nephrology, 9 (10), 574-586. doi:10.1038/nrneph.2013.171
Gillmore, J.D., Hawkins, P.N. (2013). Pathophysiology and treatment of systemic amyloidosis. NATURE REVIEWS NEPHROLOGY, 9 (10), 574-586. doi:10.1038/nrneph.2013.171
Pinney, J.H., Lachmann, H.J., Sattianayagam, P.T., Gibbs, S.D.J., Wechalekar, A.D., Venner, C.P., ...Hawkins, P.N. (2013). Renal transplantation in systemic amyloidosis - Importance of amyloid fibril type and precursor protein abundance. American Journal of Transplantation, 13 (2), 433-441. doi:10.1111/j.1600-6143.2012.04326.x
Pinney, J.H., Lachmann, H.J., Sattianayagam, P.T., Gibbs, S.D.J., Wechalekar, A.D., Venner, C.P., ...Hawkins, P.N. (2013). Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance.. AMERICAN JOURNAL OF TRANSPLANTATION, 13 (2), 433-441. doi:10.1111/j.1600-6143.2012.04326.x
Sandhu, R., Westcott, M., Pavesio, C., Rowczenio, D.M., Gilbertson, J.A., Gillmore, J.D., Gibbs, S.D.J. (2013). Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin E89K mutation. Retinal Cases and Brief Reports, 7 (3), 271-275. doi:10.1097/ICB.0b013e31828eefa2
Mahmood, S., Sachchithanantham, S., Bridoux, F., Lane, T., Rannigan, L., Foard, D., ...Whelan, C. (2013). Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years.
Pinney, J.H., Whelan, C.J., Petrie, A., Dungu, J., Banypersad, S.M., Sattianayagam, P., ...Wassef, N. (2013). Senile systemic amyloidosis: clinical features at presentation and outcome.. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2 (2), doi:10.1161/JAHA.113.000098
Mangione, P.P., Esposito, G., Relini, A., Raimondi, S., Porcari, R., Giorgetti, S., ...Goto ., Y. (2013). Structure, folding dynamics and amyloidogenesis of Asp76Asn β2-microglobulin: roles of shear flow, hydrophobic surfaces and α crystallin.. J Biol Chem,
Pinney, J.H., Smith, C.J., Taube, J.B., Lachmann, H.J., Venner, C.P., Gibbs, S.D.J., ...Whelan, C.J. (2013). Systemic Amyloidosis in England: An epidemiological study. British Journal of Haematology, 161 (4), 525-532. doi:10.1111/bjh.12286
Pinney, J.H., Smith, C.J., Taube, J.B., Lachmann, H.J., Venner, C.P., Gibbs, S.D.J., ...Whelan, C.J. (2013). Systemic amyloidosis in England: an epidemiological study.. Br J Haematol, 161 (4), 525-532. doi:10.1111/bjh.12286
Sachchithanantham, S., Mahmood, S.A., Pinney, J.H., Gillmore, J.D., Lachmann, H.J., Lane, T., ...Wechalekar, A.D. (2013). Treatment outcomes of 299 elderly (>= 75 years) patients with systemic AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161 21.
Sachchithanantham, S., Baginska, A., Rowczenio, D., Mahmood, S., Sayed, R., Patel, K., ...Whelan, C. (2013). Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis.

2012

Venner, C.P., Lane, T., Foard, D., Rannigan, L., Mahmood, S., Gibbs, S.D.J., ...Whelan, C. (2012). A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.
Sattianayagam, P.T., Hahn, A.F., Whelan, C.J., Gibbs, S.D.J., Pinney, J.H., Stangou, A.J., ...Lachmann, H.J. (2012). Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.. EUROPEAN HEART JOURNAL, 33 (9), 1120-1127. doi:10.1093/eurheartj/ehr383
Mahmood, S., Venner, C.P., Lane, T., Rannigan, L., Foard, D., Pinney, J., ...Lachmann, H.J. (2012). Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.
Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D.J., Pinney, J.H., ...Hawkins, P.N. (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.. BLOOD, 119 (19), 4387-4390. doi:10.1182/blood-2011-10-388462
Dubrey, S.W., Rosser, G., Dahdal, M.T., Gillmore, J.D. (2012). Diagnostic dilemma and sudden death outcome: a case of amyloid cardiomyopathy.. CLINICAL MEDICINE, 12 (6), 596-597. doi:10.7861/clinmedicine.12-6-596
Sattianayagam, P.T., Gibbs, S.D.J., Rowczenio, D., Pinney, J.H., Wechalekar, A.D., Gilbertson, J.A., ...Gillmore, J.D. (2012). Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation. Journal of Internal Medicine, 272 (1), 36-44. doi:10.1111/j.1365-2796.2011.02470.x
Sattianayagam, P.T., Gibbs, S.D.J., Rowczenio, D., Pinney, J.H., Wechalekar, A.D., Gilbertson, J.A., ...Gillmore, J.D. (2012). Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation.. JOURNAL OF INTERNAL MEDICINE, 272 (1), 36-44. doi:10.1111/j.1365-2796.2011.02470.x
Valleix, S., Gillmore, J.D., Bridoux, F., Mangione, P.P., Dogan, A., Nedelec, B., ...Lacombe, C. (2012). Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.. NEW ENGLAND JOURNAL OF MEDICINE, 366 (24), 2276-2283. doi:10.1056/nejmoa1201356
Venner, P., Jaccard, A., Hawkins, P., Roussel, M., Gibbs, S., Gillmore, J., ...Parameswaran, H. (2012). MUTLI-INSTITUTIONAL EXPERIENCE WITH UPFRONT CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CVD) IN THE TREATMENT OF AL AMYLOIDOSIS.
Dungu, J., Whelan, C.J., Gibbs, S.D., Pinney, J.H., Banypersad, S.M., Venner, C.P., ...Hawkins, P.N. (2012). Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis.. J Cardiovasc Magn Reson, 14 Suppl 1 O87-. doi:10.1186/1532-429X-14-S1-O87
Dungu, J., Whelan, C.J., Gibbs, S.D.J., Pinney, J.H., Banypersad, S.M., Venner, C.P., ...Hawkins, P.N. (2012). PATTERNS OF LATE GADOLINIUM ENHANCEMENT PREDICT SURVIVAL IN CARDIAC AMYLOIDOSIS: A SYSTEMATIC REVIEW OF 95 CASES WITH AL OR TTR TYPE.
Dungu, J., Sattianayagam, P.T., Whelan, C.J., Gibbs, S.D.J., Pinney, J.H., Banypersad, S.M., ...Wechalekar, A. (2012). The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients.. AMERICAN HEART JOURNAL, 164 (1), 72-79. doi:10.1016/j.ahj.2012.04.013
Roussel, M., Palladini, G., Gibbs, S.D.J., Venner, C.P., Fermand, J.-.P., Lachmann, H.J., ...Jaccard, A. (2012). Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis.
Roussel, M., Palladini, G., Gibbs, S.D.J., Venner, C.P., Fermand, J.-.P., Lachmann, H.J., ...Jaccard, A. (2012). Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis.

2011

Wechalekar, A.D., Gillmore, J.D., Wassef, N., Lachmann, H.J., Whelan, C., Hawkins, P.N. (2011). Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.. Haematologica-Hematology Journal, 96 (7), 1079-1080. doi:10.3324/haematol.2011.040493
Lane, T., Rannigan, L., Foard, D., Wechalekar, A., Gibbs, S., Pinney, J., ...Hawkins, P.N. (2011). ALchemy - A Large Prospective 'Real World' Study of Chemotherapy in AL Amyloidosis.
Rowczenio, D., Dogan, A., Theis, J.D., Vrana, J.A., Lachmann, H.J., Wechalekar, A.D., ...Sattianayagam, P.T. (2011). Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.. AMERICAN JOURNAL OF PATHOLOGY, 179 (4), 1978-1987. doi:10.1016/j.ajpath.2011.06.024
Kowalewska-Zietek, J., Dawson, T.P., Damodaran, D., Gillmore, J.D. (2011). An unusual cause of carpal tunnel syndrome.. Practical Neurology, 11 (6), 352-354. doi:10.1136/practneurol-2011-000037
Venner, C.P., Gillmore, J.D., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D.J., ...Hawkins, P.N. (2011). Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (> 75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival.
Venner, C.P., Gillmore, J.D., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D.J., ...Hawkins, P.N. (2011). Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival.
Wechalekar, A., Schonland, S.O., Kastritis, E., Hawkins, P.N., Dimopoulos, M.A., Russo, P., ...Milani, P. (2011). European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease.
Pinney, J.H., Lachmann, H.J., Bansi, L., Wechalekar, A.D., Gilbertson, J.A., Rowczenio, D., ...Wassef, N.L. (2011). Outcome in renal Al amyloidosis after chemotherapy.. JOURNAL OF CLINICAL ONCOLOGY, 29 (6), 674-681. doi:10.1200/JCO.2010.30.5235
Bridoux, F., Ronco, P., Gillmore, J.D. (2011). Renal transplantation in light chain amyloidosis: coming out of the cupboard. Nephrol Dial Transplant, 26 (6), 1766-1768.
Bridoux, F., Ronco, P., Gillmore, J., Fermand, J.-.P. (2011). Renal transplantation in light chain amyloidosis: coming out of the cupboard.. NEPHROL DIAL TRANSPL, 26 (6), 1766-1768. doi:10.1093/ndt/gfr191
Pinney, J.H., Lachmann, H.J., Gillmore, J.D., Wechalekar, A., Gibbs, S.D.J., Sattianayagam, P., ...McCarthy, C.A. (2011). SENILE SYSTEMIC AMYLOIDOSIS: A COMMON CAUSE OF HEART FAILURE IN THE ELDERLY?.
Sattianayagam, P., Gibbs, S.D., Pinney, J.H., Wechalekar, A.D., Lachmann, H.J., Philip, H.N., ...Gillmore, J.D. (2011). The Role of Liver Transplantation in Hereditary Non-Neuropathic Systemic Amyloidosis.

2010

Wechalekar, A.D., Kastritis, E., Merlini, G., Hawkins, P.N., Dimopoulos, M.A., Gillmore, J.D., ...Palladini, G. (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis.
Wechalekar, A.D., Kastritis, E., Merlini, G., Hawkins, P.N., Dimopoulos, M.A., Gillmore, J.D., ...Palladini, G. (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. BLOOD, 116 (21), 435.
Lane, T., Foard, D.M., Wechalekar, A.D., Gibbs, S.D.J., Lachmann, H.J., Sattianayagam, P.T., ...Hawkins, P.N. (2010). ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK.
Gibbs, S., Vanderpump, M., Hutt, D., Sattianayagam, P., Pinney, J., Wassef, N., ...Wechalekar, A. (2010). AN ANALYSIS OF THE ENDOCRINE DISEASE ASSOCIATED WITH SYSTEMIC AL AMYLOIDOSIS.
Gibbs, S., Vanderpump, M., Hutt, D., Sattianayagam, P., Pinney, J., Wassef, N., ...Wechalekar, A. (2010). AN ANALYSIS OF THE ENDOCRINE DISEASE ASSOCIATED WITH SYSTEMIC AL AMYLOIDOSIS.
Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., ...Millar, D.J. (2010). Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468 (7320), 93-97. doi:10.1038/nature09494
Whelan, C.J., Pawarova, B., De Cruz, M., Lachmann, H.J., Sattianayagam, P.T., Gibbs, S.D.J., ...Wechalekar, A.D. (2010). Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities.
Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., ...Palladini, G. (2010). Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.. JOURNAL OF CLINICAL ONCOLOGY, 28 (6), 1031-1037. doi:10.1200/JCO.2009.23.8220
Whelan, C.J., Pawarova, B., De Cruz, M., Lachmann, H.J., Sattianayagam, P.T., Gibbs, S.D.J., ...Hawkins, P.N. (2010). Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis.
Dogan, A., Theis, J.D., Vrana, J.A., Jimenez-Zepeda, V.H., Lacy, M.Q., Leung, N., ...Gilbertson, J.A. (2010). Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2).
Pinney, J.H., Lachmann, H.J., Bansi, L., Wechalekar, A.D., Gilbertson, J.A., Rowczenio, D., ...Wassef, N.L. (2010). Clinical outcome of systemic AL amyloidosis affecting the kidneys.
Gibbs, S.D.J., Gillmore, J.D., Sattianayagam, P.T., Lachmann, H.J., Lane, T., Goodman, H.J.B., ...Hutt, D.F. (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study.
Rowczenio, D.M., Lachmann, H.J., Gibbs, S.D.J., Gilbertson, J.A., Hunt, T., Russell, T.L., ...Whelan, C.J. (2010). Experience of ATTR in a single centre: findings among 220 patients.
Sattianayagam, P., Gibbs, S.D., Wechalekar, A.D., Lachmann, H.J., Gilbertson, J.A., Philip, H.N., Gillmore, J.D. (2010). Hepatic Al Amyloidosis - A 10-Year Experience at the United Kingdom National Amyloidosis Centre (NAC).
Gillmore, J.D., Lachmann, H.J., Wechalekar, A., Hawkins, P.N. (2010). Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.. BLOOD, 115 (21), 4313. doi:10.1182/blood-2010-01-261750
Rowczenio, D.M., Lachmann, H.J., Gibbs, S.D.J., Gilbertson, J.A., Hunt, T., Russell, T.L., ...Whelan, C.J. (2010). Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants.
Gibbs, S., Pinney, J., Sattianayagam, P., Lane, T., Rowczenio, D., Wechalekar, A., ...Gillmore, J. (2010). LIGHT CHAIN DEPOSITION DISEASE (LCDD) VERSUS AL AMYLOIDOSIS: DIFFERENCES IN NATURAL HISTORY AND TREATMENT?.
Gibbs, S., Pinney, J., Sattianayagam, P., Lane, T., Rowczenio, D., Wechalekar, A., ...Gillmore, J. (2010). LIGHT CHAIN DEPOSITION DISEASE (LCDD) VERSUS AL AMYLOIDOSIS: DIFFERENCES IN NATURAL HISTORY AND TREATMENT?.
Gibbs, S.D.J., Pinney, J.H., Sattianayagam, P.T., Wechalekar, A.D., Lane, T., Rowczenio, D.M., ...Hawkins, P.N. (2010). Light chain deposition disease (LCDD): a case series of 24 patients.
Gilbertson, J.A., Hunt, T., Wechalekar, A.D., Lachmann, H.J., Hawkins, P.N., Gillmore, J.D. (2010). Localised amyloid at injection sites derived from porcine and human insulin.
Sattianayagam, P.T., Rowczenio, D.M., Gibbs, S.D.J., Trojer, H., Russell, T.L., Pinney, J.H., ...Pepys, M.B. (2010). Natural history of hereditary lysozyme amyloidosis.
Wechalekar, A.D., Merlini, G., Gillmore, J.D., Russo, P., Lachmann, H.J., Perlini, S., ...Palladini, G. (2010). N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis.
Palladini, G., Hawkins, P.N., Foli, A., Lachmann, H.J., Perlini, S., Gillmore, J., ...Wechalekar, A.D. (2010). N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure.
Sattianayagam, P.T., Gibbs, S.D.J., Wechalekar, A.D., Lachmann, H.J., Hawkins, P.N., Gillmore, J.D. (2010). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 9 (10), 2443. doi:10.1111/j.1600-6143.2009.02790.x
Sattianayagam, P.T., Hahn, A., Gibbs, S.D.J., Whelan, C.J., Rowczenio, D.M., Trojer, H., ...Wechalekar, A.D. (2010). Phenotype and natural history of transthyretin alanine 60 ( T60A) amyloidosis.
Lachmann, H.J., Harding, S., Wechalekar, A., Gillmore, J.D., Amft, E.N., Hawkins, P.N. (2010). Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases.
Lachmann, H.J., Harding, S., Wechalekar, A., Gillmore, J.D., Amft, E.N., Hawkins, P.N. (2010). Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases.
Lachmann, H.J., Gillmore, J.D. (2010). Renal amyloidosis.. British journal of hospital medicine (London, England : 2005), 71 (2), 83-86. doi:10.12968/hmed.2010.71.2.46485
Lachmann, H.J., Gillmore, J.D. (2010). Renal amyloidosis.. BRITISH JOURNAL OF HOSPITAL MEDICINE, 71 (2), 83-86. doi:10.12968/hmed.2010.71.2.46485
Gibbs, S.D.J., Sattianayagam, P.T., Pinney, J.H., Gilbertson, J.A., Lachmann, H.J., Wechalekar, A.D., ...Gillmore, J.D. (2010). Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease. INTERNAL MEDICINE JOURNAL, 40 (2), 167-168. doi:10.1111/j.1445-5994.2009.02127.x
Gibbs, S.D.J., Sattianayagam, P.T., Whelan, C.J., De Cruz, M., Abreu, J.M., Pinney, J.H., ...Lachmann, H.J. (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment.
Hutt, D.F., Lane, T., Gillmore, J.D., Lachmann, H.J., Gibbs, S.D.J., Sattianayagam, P.T., ...Wechalekar, A.D. (2010). Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis.
Wechalekar, A.D., Harding, S., Lachmann, H.J., Gillmore, J.D., Wassef, N.L., Thomas, M., ...Bradwell, A.R. (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis.
Dember, L.M., Gillmore, J.D., Lewis, W.D., Pasquali, S., Schoenland, S.O., Semigran, M.J., Hawkins, P.N. (2010). Solid organ transplantation for non-TTR amyloidoses: consensus opinion.
Sattianayagam, P.T., Gibbs, S.D.J., Wechalekar, A.D., Lachmann, H.J., Whelan, C.J., Pinney, J.H., ...Gillmore, J.D. (2010). Solid organ transplantation in AL amyloidosis.
Sattianayagam, P.T., Gibbs, S.D.J., Pinney, J.H., Wechalekar, A.D., Lachmann, H.J., Whelan, C.J., ...Gillmore, J.D. (2010). Solid Organ Transplantation in AL Amyloidosis. AMERICAN JOURNAL OF TRANSPLANTATION, 10 (9), 2124-2131. doi:10.1111/j.1600-6143.2010.03227.x
Lachmann, H.J., Gillmore, J.D., Wechalekar, A.D., Sattianayagam, P.T., Gibbs, S.D.J., Pinney, J.H., ...Gilbertson, J.A. (2010). Survival on dialysis and outcome after renal transplantation in AA amyloidosis.
Gillmore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J.B., ...Hawkins, P.N. (2010). Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.. Brit J Haematol, 148 (5), 760-767. doi:10.1111/j.1365-2141.2009.08036.x
Grünfeld, J.-.P. (2010). Systemic diseases: from amyloidosis to cryoglobulinemia.. Clinical journal of the American Society of Nephrology : CJASN, 5 (11), 1912-1915. doi:10.2215/cjn.08130910
Gillmore, J.D., Cocks, K., Gibbs, S.D.J., Sattianayagam, P., Lane, T., Lachmann, H.J., ...Morgan, G. (2010). UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design.
Hunt, T., Gilbertson, J.A., Lachmann, H.J., Gillmore, J.D., Gibbs, S.D.J., Sattianayagam, P.T., ...Wechalekar, A.D. (2010). Unraveling the clonal B cell disease underlying localised AL amyloidosis.

2009

Wechalekar, A., Merlini, G., Gillmore, J.D., Russo, P., Lachmann, H.J., Obici, L., ...Palladini, G. (2009). A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response. CLINICAL LYMPHOMA & MYELOMA, 9 S51. doi:10.1016/S1557-9190(11)70539-X
Wechalekar, A.D., Wassef, N.L., Gibbs, S.D.J., Gillmore, J., Dike, F., Lachmann, H., ...Hawkins, P.N. (2009). A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP..
de Vallière, S., Mary, C., Joneberg, J.E., Rotman, S., Bullani, R., Greub, G., ...Tarr, P.E. (2009). AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient.. The American journal of tropical medicine and hygiene, 81 (2), 209-212. doi:10.4269/ajtmh.2009.81.209
Sattianayagam, P.T., Hawkins, P.N., Gillmore, J.D. (2009). Amyloid and the GI tract. Expert Rev Gastroenterol Hepatol, 3 (6), 615-630.
Sattianayagam, P., Hawkins, P., Gillmore, J. (2009). Amyloid and the GI tract.. Expert Rev Gastroenterol Hepatol, 3 (6), 615-630. doi:10.1586/egh.09.59
Bridoux, F., Jaccard, A., Sirac, C., Gillmore, J.D., Cogne, M., Grateau, G., Touchard, G. (2009). Atteintes uro-néphrologiques au cours des maladies systémiques. In Bagnis, C.I., Cacoub, P., Deray, G. (Eds.), Atteintes uro-néphrologiques au cours des maladies systémiques. .
Wechalekar, A.D., Offer, M., Gillmore, J.D., Hawkins, P.N., Lachmann, H.J. (2009). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.. Nature Clinical Practice Cardiovascular Medicine, 6 (2), 128-133.
Sattianayagam, P., Gibbs, S.D.J., Waterworth, C., De Cruz, M., Pawarova, B., Rowcenzio, D., ...Gillmore, J.D. (2009). Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy secondary to variant transthyretin (Ala60).
Gibbs, S.D.J., Sattianayagam, P.T., Hawkins, P.N., Gillmore, J.D. (2009). Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience.. INTERNAL MEDICINE JOURNAL, 39 (11), 786-787. doi:10.1111/j.1445-5994.2009.02017.x
De Vallière, S., Mary, C., Joneberg, J.E., Rotman, S., Bullani, R., Greub, G., ...Tarr, P.E. (2009). Case report: AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. American Journal of Tropical Medicine and Hygiene, 81 (2), 209-212. doi:10.4269/ajtmh.2009.81.209
Gillmore, J., Cocks, K., Gibbs, S.D.J., Sattianayagam, P.T., Lane, T., Lachmann, H., ...Morgan, G.J. (2009). Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial.
Sattianayagam, P.T., Gibbs, S.D.J., Gilbertson, J., Hawkins, P.N., Gillmore, J.D. (2009). Diagnosing amyloid with a rectal biopsy-how important is it?. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24 A258.
Gillmore, J.D., Lachmann, H.J., Rowczenio, D., Gilbertson, J.A., Zeng, C.H., Liu, Z.H., ...Hawkins, P.N. (2009). Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.. Journal of the American Society of Nephrology, 20 (2), 444-451.
de Cruz, M., Pawarova, B., Lachmann, H., Gillmore, J., Gibbs, S., Sattianayagam, P., ...Wechalekar, A.D. (2009). Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.
Wechalekar, A.D., Wassef, N., Lachmann, H., Sattianayagam, P., Gibbs, S.D.J., Gillmore, J., Hawkins, P.N. (2009). HIGH EARLY MORTALITY AND POOR OUTCOMES FOR PATIENTS WITH AL AMYLOIDOSIS PRESENTING WITH HIGH SERUM FREE LIGHT CHAINS - A NEW RISK STRATIFICATION MODEL.
Wechalekar, A.D., Wassef, N., Lachmann, H., Sattianayagam, P., Gibbs, S.D.J., Gillmore, J., Hawkins, P.N. (2009). HIGH EARLY MORTALITY AND POOR OUTCOMES FOR PATIENTS WITH AL AMYLOIDOSIS PRESENTING WITH HIGH SERUM FREE LIGHT CHAINS - A NEW RISK STRATIFICATION MODEL.
Gibbs, S.D.J., Gillmore, J.D., Sattianayagam, P.T., Offer, M., Lachmann, H.J., Hawkins, P.N., Wechalekar, A.D. (2009). In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.
Gibbs, S.D.J., Sattianayagam, P.T., Gillmore, J.D., Offer, M., Lachmann, H.J., Hawkins, P.N., Wechalekar, A.D. (2009). Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.
Sattianayagam, P.T., Gibbs, S.D., Wechalekar, A.D., Lachmann, H.J., Hawkins, P.N., Gillmore, J.D. (2009). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 10 2443-.
Gibbs, S.D., Sattianayagam, P.T., Wechalekar, A.D., Lachmann, H.J., Hawkins, P.N., Gillmore, J.D. (2009). Solid Organ Transplantation in AL Amyloidosis: Lessons Learned and Its Current Role. CLINICAL LYMPHOMA & MYELOMA, 9 S71. doi:10.1016/S1557-9190(11)70585-6
Sattianayagam, P., Gibbs, S.D., Wechalekar, A., Gilbertson, J.A., Lachmann, H.J., Philip, H.N., Gillmore, J.D. (2009). Systemic AA Amyloidosis in Crohn's Disease (CD): A Serum Amyloid P Component (SAP) Scintigraphy Study.
Sattianayagam, P., Gibbs, S., Hawkins, P., Gillmore, J. (2009). Systemic AL (light-chain) amyloidosis and the gastrointestinal tract.. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 44 (11), 1384-1385. doi:10.3109/00365520903254296
Sattianayagam, P.T., Hawkins, P.N., Gillmore, J.D. (2009). Systemic amyloidosis and the gastrointestinal tract.. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 6 (10), 608-617. doi:10.1038/nrgastro.2009.147
Gibbs, S.D.J., De Cruz, M., Sattianayagam, P.T., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N., Wechalekar, A.D. (2009). Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment..

2008

Wechalekar, A.D., Lachmann, H.J., Goodman, H.J., Bradwell, A., Hawkins, P.N., Gillmore, J.D. (2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112 (10), 4009-4016.
Offer, M., Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. (2008). AL amyloidosis in the elderly: A review of 330 patients.
Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (2008). Amyloid and immunotactoid glomerulopathy. In Barratt, J., Harris, K., Topham, P. (Eds.), Oxford Desk References: Nephrology. (pp. 150-157). Oxford University Press.
Gillmore, J.D., Hawkins, P.N. (2008). Amyloidosis. In The Handbook of Systemic Autoimmune Diseases; The Kidney in Systemic Diseases. (pp. 385-398). Oxford: Elsevier Science.
Gregory, M.E., Carey, M., Hawkins, P.N., Banerjee, S., Gillmore, J.D. (2008). Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant trasnthyretin, Phe33 Val.. British Journal of Ophthalmology, 92 (1), 34-35.
Lachmann, H.J., Goodman, H.J.B., Gillmore, J.D., Wechalekar, A., Rowczenio, D.M., Bybee, A., Hawkins, P.N. (2008). Comparison of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant.
Wechalekar, A.D., Lachmann, H.L., Offer, M., Hawkins, P.N., Gillmoe, J.D. (2008). Efficacy of bortezomib in systemic AL amyloidosis with relapse/refractory clonal disease.. Haematologica, 93 (2), 295-298.
Lachmann, H.J., Wechalekar, A.D., Gillmore, J.D. (2008). High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.. NEW ENGLAND JOURNAL OF MEDICINE, 358 (1), 91-92.
Fry, A.C., Gillmore, J.D., Maxwell, P.H., O'Callaghan, C.A., Summers, S.A. (2008). Nephrology - Module 11. In Firth, J., Maxwell, P.H. (Eds.), RCP Medical Masterclass. Wiley-Blackwell.
Wechalekar, A., Lachmann, H., Gillmore, J., Offer, M., Joshi, J., Hawkins, P. (2008). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
Wechalekar, A.D., Hawkins, P.N., Gillmore, J.D. (2008). Perspective in treatment of amyloidosis. British Journal of Haematology, 140 (4), 365-377.
Gibbs, S.D.J., Sattianayagam, P.T., Lachmann, H.J., Offer, M., Gillmore, J.D., Hawkins, P.N., Wechalekar, A. (2008). Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.
Wechalekar, A., Merlini, G., Gillmore, J.D., Russo, P., Lachmann, H.J., Obici, L., ...Palladini, G. (2008). Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.
Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., ...Palladini, G. (2008). Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis.

2007

Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. (2007). A profile of 44 long term survivors (> 10yrs) with AL amyloidosis.
Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. (2007). Abnormal NT-ProBNP in AL amyloidosis patients without cardiac involvement at diagnosis - A predictor of subsequent cardiac involvement.
Gillmore, J.D., Hawkins, P.N. (2007). Chapter 21 Amyloidosis. Handbook of Systemic Autoimmune Diseases, 7 383-396. doi:10.1016/S1571-5078(07)07021-3
Wechalekar, A.D., Gillmore, J.D., Lachmann, H.J., Offer, M., Hawkins, P.N. (2007). Clinical profile and treatment outcome in 103 patients with al amyloidosis associated with IGM paraproteinaemia.
Lachmann, H.J., Goodman, H.J.B., Gilbertson, J.A., Gallimore, J.R., Sabin, C.A., Gillmore, J.D., Hawkins, P.N. (2007). Natural history and outcome in systemic AA amyloidosis. New England Journal of Medicine, 356 (23), 2361-2371. doi:10.1056/NEJMoa070265
Wechalekar, A.D., Gillmore, J.D., Lachmann, H.J., Offer, M., Hawkins, P.N. (2007). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N., Gillmore, J.D. (2007). Safety and efficacy of risk adapted cyclophosphamide,thalidomide and dexamethasone in systemic AL amyloidosis. Blood, 109 (2), 457-464. doi:10.1182/blood-2006-07-035352

2006

Gillmore, J.D., Offer, M., Lachmann, H.J., Goodman, H.J., Tennent, G.A., Gallimore, J.R., ...Hawkins, P.N. (2006). A pilot study of the tolerability, safety and efficacy of CPHPC in patients with systemic amyloidosis.
Lachmann, H.J., Goodman, H.J.B., Joshi, J.J., Gilbertson, J.A., Gillmore, J.D., Bybee, A., ...Hawkins, P.N. (2006). Characterisation of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant.
Gillmore, J.D., Hawkins, P.N. (2006). Drug Insight: emerging therapies for amyloidosis.. NATURE CLINICAL PRACTICE NEPHROLOGY, 2 (5), 263-270. doi:10.1038/ncpneph0169
Wechalekar, A., Gillmore, J., Lachmann, H., Offer, M., Hawkins, P. (2006). Efficacy and safety of bortezomib in systemic AL amyloidosis - A preliminary report..
Gillmore, J.D., Hawkins, P.N. (2006). Emerging drug therapies for amyloidosis. Nature Clinical Practice Nephrology, 2 (5), 263-270.
Perz, J.B., Rahemtulla, A., Giles, C., Szydlo, R.M., Davis, J., Gopaul, D., ...Apperley, J.F. (2006). Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 37 (10), 937-943.
Offer, M., Wechalekar, A.D., Gillmore, J.D., Lachmann, H.J., Hawkins, P.N. (2006). Natural history and outcome of amyloidosis in the elderly.
Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Offer, M., Joshi, J.J., Hawkins, P.N. (2006). NT-ProBNP in AL amyloidosis: changes after chemotherapy and association with survival.
Gillmore, J.D., Stangou, A.J., Lachmann, H.J., Goodman, H.J., Wechalekar, A.D., Acheson, J., ...Rowczenio, D. (2006). Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant, 6 (10), 2342-2347. doi:10.1111/j.1600-6143.2006.01507.x
Goodman, H.J., Gillmore, J.D., Lachmann, H.J., Wechalekar, A.D., Bradwell, A.R., Hawkins, P.N. (2006). Outcome of autologous transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134 (4), 417-425.
Connolly, J., Gillmore, J.D., Lachmann, H.J., Davenport, A., Hawkins, P.N., Woolfson, R.G. (2006). Renal amyloidosis in injection drug users. Q J Med 2006; (In press). QJM, 99 (11), 737-742.
Connolly, J.O., Gillmore, J.D., Lachmann, H.J., Davenport, A., Hawkins, P.N., Woolfson, R.G. (2006). Renal amyloidosis in intravenous drug users.. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 99 (11), 737-742. doi:10.1093/qjmed/hcl092
Hawkins, P.N., Wechalekar, A.D., Goodman, H.J.B., Lachmann, H.J., Offer, M., Gillmore, J.D. (2006). Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.
Rowczenio, D.M., Lachmann, H.J., Gillmore, J.D., Wechalekar, A.D., Gilbertson, J.A., Goodman, H.J.B., ...Bybee, A. (2006). Screening for patients with hereditary systemic amyloidosis.
Gillmore, J.D., Goodman, H.J., Lachmann, H.J., Offer, M., Wechalekar, A.D., Joshi, J., ...Hawkins, P.N. (2006). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107 (3), 1227-1229. doi:10.1182/blood-2005-08-3253

2005

Gillmore, J.D., Wechalekar, A.D., Goodmarn, H.J.B., Lachmann, H.J., Offer, M., Joshi, J., Hawkins, R.N. (2005). Cardiac followed by autologous stem cell transplantation for systemic AL amyloidosis..
Wechalekar, A.D., Goodman, H.J.B., Gillmore, J.D., Lachmann, H.J., Offer, M., Bradwell, A.R., Hawkins, P.N. (2005). Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia..
Wechalekar, A.D., Goodman, H.J.B., Gillmore, J.D., Lachmann, H.J., Offer, M., Bradwell, A.R., Hawkins, P.N. (2005). Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis..
Stangou, A.J., Rela, M., O'Grady, J., Heneghan, M., Mathias, C.J., Muiesan, P., ...Lachmann, H. (2005). Fibrinogen A alpha-chain amyloidosis: Clinical features and the role of combined liver and kidney transplantation.
Offer, M., Wechalekar, A.D., Goodman, H.J.B., Gillmore, J.D., Lachmann, H.J., Bradwell, A.R., Hawkins, P.N. (2005). Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay..
Wechalekar, A.D., Lachmann, H.J., Gillmore, J.D., Goodman, H.J.B., Offer, M., Hawkins, P.N. (2005). The role of renal transplantation in systemic AL amyloidosis..

2004

Gillmore, J.D., Hutchinson, W.L., Herbert, J., Bybee, A., Mitchell, D.A., Hasserjian, R.P., ...Pepys, M.B. (2004). Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination?. Immunology, 112 (2), 255-264.
Bird, J., Cavenagh, J., Hawkins, P., Lachmann, H., Mehta, A., Samson, D. (2004). Guidelines on the diagnosis and management of AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 125 (6), 681-700.

2003

Lachmann, H.J., McDermott, M.F., Hawkins, P.N. (2003). AA amyloidosis complicating the hereditary periodic fever syndromes..
Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B., Hawkins, P.N. (2003). Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol, 122 (1), 78-84. doi:10.1046/j.1365-2141.2003.04433.x
Gillmore, J.D., Hutchinson, W.L., Mitchell, D.A., Herbert, J., Botto, M., Walport, M.J., Pepys, M.B. (2003). Studies of serum amyloid P component (SAP) and antinuclear autoimmunity..

2002

Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Hawkins, P.N. (2002). Changes in the concentration of circulating free immunoglobulin light chains and outcome in systemic AL amyloidosis following chemotherapy..
Lachmann, H.J., Gallimore, R., Gillmore, J.D., Smith, L., Bradwell, A.R., Bradwell, A.R., Hawkins, P.N. (2002). Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis.. CLINICAL CHEMISTRY, 48 (6), A165.
Lachmann, H.J., Gallimore, R., Gillmore, J.D., Smith, L., Bradwell, A.R., Hawkins, P.N. (2002). Detection of monoclonal free light chains by nephelometry in 262 patients with systemic AL amyloidosis.. CLINICAL CHEMISTRY, 48 (6), A164-A165.
Lachmann, H.J., Booth, D.R., Bybee, A., Gillmore, J.D., Hawkins, P.N. (2002). Frequency of hereditary systemic amyloidosis masquerading as immunoglobulin light chain, AL (primary), amyloidosis.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 13 39A.
Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., ...Hawkins, P.N. (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med, 346 (23), 1786-1791. doi:10.1056/NEJMoa013354
Lachmann, H.J., Gillmore, J.D., Pepys, M.B., Hawkins, P.N. (2002). Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy..
Shah, P.L., Gillmore, J.D., Copley, S.J., Collins, J.V., Wells, A.U., du Bois, R.M., ...Nicholson, A.G. (2002). The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases, 19 (2), 134-142.
Lachmann, H.J., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (2002). Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM, 95 (4), 211-218.

2001

Gillmore, J.D., Lovat, L.B., Persey, M.R., Pepys, M.B., Hawkins, P.N. (2001). Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet, 358 (9275), 24-29. doi:10.1016/S0140-6736(00)05252-1
Gillmore, J.D., Stangou, A.J., Tennent, G.A., Booth, D.R., O'Grady, J., Rela, M., ...Hawkins, P.N. (2001). Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation, 71 (7), 986-992.
Gillmore, J.D., Apperley, J.F., Lachmann, H.J., Barrett, A.J., Madhoo, S., Pepys, M.B., Hawkins, P.N. (2001). Combination chemotherapy for systemic AL amyloidosis. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 8 72-73.
Lachmann, H.J., Booth, D.R., Booth, S.E., Bybee, A., Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N. (2001). Hereditary systemic amyloidosis due to variant fibrinogen A alpha-chain is unexpectedly frequent in the British population. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 8 151.
Booth, D.R., Lachmann, H.J., Gillmore, J.D., Booth, S.E., Hawkins, P.N. (2001). Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. QJM, 94 (10), 527-531.

2000

Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N., Laffan, M. (2000). Bleeding symptoms and coagulation abnormalities in 337 patients with AL- amyloidosis. British Journal of Haematology, 110 (2), 454-460.
Hasserjian, R.P., Lachmann, H.J., Gillmore, J.D., Hawkins, P.M. (2000). Correlation of bone marrow findings with organ distribution and amyloid burden in 103 patients with al amyloidosis. Blood, 96 (11 PART I),
Hasserjian, R.P., Lachmann, H.J., Gillmore, J.D., Hawkins, P.N. (2000). Correlation of bone marrow findings with organ distribution and amyloid burden in 103 patients with AL amyloidosis.. BLOOD, 96 (11), 157A.
Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Rahman, V., Stangou, A.J., ...Hawkins, P.N. (2000). Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. QJM, 93 (5), 269-275.
Gillmore, J.D., Madhoo, S., Pepys, M.B., Hawkins, P.N. (2000). Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy. Nucl Med Commun, 21 (8), 735-740.
Booth, D.R., Gillmore, J.D., Lachmann, H.J., Booth, S.E., Bybee, A., Soytürk, M., ...Hawkins, P.N. (2000). The genetic basis of autosomal dominant familial Mediterranean fever. QJM, 93 (4), 217-221.
Elliott, P.M., Mahon, N.G., Matsumura, Y., Hawkins, P.N., Gillmore, J.D., McKenna, W.J. (2000). Tissue Doppler features of cardiac amyloidosis. Clinical Cardiology, 23 (9), 701-.
Booth, D.R., Stangou, A., Williams, R.S., Gillmore, J.D., Tennent, G.A., Hawkins, P.N. (2000). Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy. Human Mutation, 16 (5), 447-.

1999

Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (1999). Alpha-1 antiprotease alleles as risk factors in AA amyloidosis.
Gillmore, J.D., Lovat, L.B., Hawkins, P.N. (1999). Amyloidosis and the liver. 30 suppl 1 17-33.
Gillmore, J.D., Lovat, L.B., Hawkins, P.N. (1999). Amyloidosis and the liver.. Journal of hepatology, 30 Suppl 1 17-33.
Gillmore, J.D., Hawkins, P.N. (1999). Amyloidosis and the respiratory tract.. THORAX, 54 (5), 444-451. doi:10.1136/thx.54.5.444
Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N., Laffan, M. (1999). Bleeding symptoms and coagulation test abnormalities in 308 patients with AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 105 27.
Mumford, A.D., O'Donnell, J., Gillmore, J.D., Manning, R.A., Hawkins, P.N., Laffan, M. (1999). Bleeding symptoms and coagulation test abnormalities in 337 patients with AL amyloidosis. THROMBOSIS AND HAEMOSTASIS, 736.
Gillmore, J.D., Lovat, L.B., Persey, M.R., Madhoo, S., Gallimore, J.R., Pepys, M.B., Hawkins, P.N. (1999). Cumulative SAA production and outcome of AA amyloidosis.
Gillmore, J.D., Booth, D.R., Rela, M., Heaton, N.D., Williams, R.S., Harrison, P., ...Hawkins, P.N. (1999). Curative hepatorenal transplantation for systemic amyloidosis associated with fibrinogen alpha-chain Glu526Val in an English family.
Gillmore, J.D., Booth, D.R., Pepys, M.B., Hawkins, P.N. (1999). Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart, 82 (3), e2-.
Gillmore, J.D., Booth, D.R., Madhoo, S., Pepys, M.B., Hawkins, P.N. (1999). Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant, 14 (11), 2639-2644.
Gillmore, J.D., Apperley, J.F., Pepys, M.B., Hawkins, P.N. (1999). High dose chemotherapy for systemic AL amyloidosis.. KIDNEY INTERNATIONAL, 55 (5), 2103.
Gillmore, J.D., Apperley, J.F., Craddock, C., Madhoo, S., Pepys, M.B., Hawkins, P.N. (1999). High-dose melphalan and stem cell rescue for AL amyloidosis.
Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (1999). SAA(1) alleles as risk factors in AA amyloidosis.
Gillmore, J.D., Persey, M.R., Lovat, L.B., Madhoo, S., Pepys, M.B., Hawkins, P.N. (1999). Serum amyloid P component scintigraphy in AL amyloidosis.
Booth, D.R., Gillmore, J.D., Pepys, M.B., Hawkins, P.N. (1999). Transthyretin mutations in amyloidosis.

1998

Gillmore, J.D., Davies, J., Iqbal, A., Madhoo, S., Russell, N.H., Hawkins, P.N. (1998). Allogeneic bone marrow transplantation for systemic AL amyloidosis.. BRITISH JOURNAL OF HAEMATOLOGY, 100 (1), 226-228. doi:10.1046/j.1365-2141.1998.00527.x
Booth, D.R., Gillmore, J.D., Booth, S.E., Pepys, M.B., Hawkins, P.N. (1998). Pyrin/marenostrin mutations in familial Mediterranean fever.. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 91 (9), 603-606. doi:10.1093/qjmed/91.9.603
Booth, D.R., Booth, S.E., Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (1998). SAA1 alleles as risk factors in reactive systemic AA amyloidosis.. AMYLOID-INTERNATIONAL JOURNAL OF EXPERIMENTAL AND CLINICAL INVESTIGATION, 5 (4), 262-265. doi:10.3109/13506129809007299
Booth, D.R., Gillmore, J.D., Persey, M.R., Booth, S.E., Cafferty, K.D., Tennent, G.A., ...Pasvol, G. (1998). Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family.. Human Mutation, 12 135-.
Booth, D.R., Gillmore, J.D., Persey, M.R., Booth, S.E., Cafferty, K.D., Tennent, G.A., ...Pasvol, G. (1998). Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family. Mutations in brief no. 158. Online.. Human mutation, 12 (2), 135-. doi:10.1002/(sici)1098-1004(1998)12:2<135::aid-humu9>3.0.co;2-k

1997

Gillmore, J.D., Hawkins, P.N., Pepys, M.B. (1997). Amyloidosis: a review of recent diagnostic and therapeutic developments.. BRITISH JOURNAL OF HAEMATOLOGY, 99 (2), 245-256. doi:10.1046/j.1365-2141.1997.303194.x
Wu, E.B., Witherspoon, M.L., Gillmore, J.D., Pattison, J.M., Chambers, J.B. (1997). The role of transesophageal echocardiography in patients with chronic renal failure at low and high risk of endocarditis.. JOURNAL OF HEART VALVE DISEASE, 6 (3), 249-252.

1900

Gilbertson, J.A., Gillmore, J.D., Hawkins, P.N. (1900). Experience from a Large Referral Centre 978-3-319-19293-2. In Picken, M.M., Dogan, A., Herrera, G.A. (Eds.), Amyloid and Related Disorders 2nd Edition. .
Law, S., Lachmann, H., Rezk, T., Wechalekar, A., Gillmore, J., Motallebzadeh, R. (1900). Outcome of renal transplantation in systemic amyloidosis. Presented at: British Transplantation Society Harrogate, UK.